Determination method of human galectin-3 protein level and application

The antibody detection method targeting specific amino acid sequences of human Galectin-3 solves the problem of accurate quantification of Galectin-3 in existing technologies, enabling accurate detection of both full-length and total Galectin-3 protein, which is applicable to the diagnosis and monitoring of various diseases.

CN118978593AActive Publication Date: 2024-11-19SHENZHEN RUIMENG INNOVATION BIOTECHNOLOGY CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202311477503.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-11-07
Publication Date
2024-11-19
Estimated Expiration
2043-11-07

Smart Images

  • Figure CN118978593A_ABST
    Figure CN118978593A_ABST
Patent Text Reader

Abstract

The invention provides an antibody or an antigen-binding portion thereof for binding to human galectin-3, and an antibody combination product. The present application also provides a kit for detecting the level of galectin-3 in a sample from a human subject and uses thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application generally relates to the field of biological detection, and in particular, the present application provides antibodies or antigen-binding portions thereof for binding to human galectin-3 and antibody combination products. The present application also provides a kit for detecting the level of galectin-3 in a sample from a human subject and its use. Background Art

[0002] Galectin (Gal) is a member of the animal lectin superfamily and is widely distributed in various animals. Since it was first isolated in 1976, 15 types of Gal have been discovered so far, named Gal-1 to Gal-15 according to the time of discovery. They are divided into three categories according to their structural differences and the number of conserved sugar recognition domains in their polypeptide chains: (1) Prototype galectins (galectin-1, -2, -5, -7, -10, -11, -13, -14 and -15) contain a CRD; (2) Tandem repeat galectins (galectin-4, -6, -8, -9 and -12) have two CRDs separated by a linker region in a single polypeptide; (3) Chimeric galectin (Galectin-3) contains a CRD connected to an extended non-lectin N-terminal domain. Although they differ in structure, they share common features: a similar CRD consisting of 135 amino acids (complementarity determining region) and affinity for β-galactoside.

[0003] Galectin-3 is the only member of the chimeric Gal and one of the most studied members of the galectin family. The human Galectin-3 gene is located on chromosome 14q21-22, with a total length of about 17kb, containing 250 amino acid residues, a molecular weight of about 29.31KD, and contains 6 exons and 5 introns. Human Galectin-3 has three domains: (1) 1-12 amino acids NH2-(amino) terminal, which determines the cell localization and is also required for the highly conserved ser6 residue to participate in the anti-apoptotic activity of Galectin-3; (2) collagen repeat sequences rich in glycine, tyrosine, and proline, which function as substrates for matrix metalloproteinases (MMPs); (3) a globular carbohydrate binding site (CRD), COOH-(carboxyl) terminal.

[0004] Schematic diagram of the Galectin-3 protein structure Figure 1 shown.

[0005] Galectin-3 has a collagen-like domain, and matrix metalloproteinases also have such a structure. The similar structure makes Galectin-3 a substrate for matrix metalloproteinases. It is easily decomposed by matrix metalloproteinases, especially by MMP-2 or MMP-9. After MMP-2 or MMP-9 decomposes Galectin-3, a 22kD sugar recognition domain and a 9kD amino acid residue are generated to form a terminal fragment. The decomposed Galectin-3 can enhance angiogenesis and is more likely to play a role in tumor metastasis and invasion. The closer Galectin-3 is to matrix cancer cells, the more invasive it will be. It has been reported in the literature that in the study of breast cancer, the decomposed Galectin-3 activates PKC or induces GTPase, upregulates the pFAK pathway, enhances the chemotaxis of vascular endothelial cells, promotes the migration and chemotaxis of vascular endothelial cells, and thus promotes the formation of new blood vessels. Tumor-related factor mucin 1 is a ligand of Galectin-3. Galectin-3 increases its adhesion to tumors, thereby indirectly playing a role in tumor cell invasion.

[0006] Matrix metalloproteinases (MMPs) are endopeptidases that play a key role in the degradation of the extracellular matrix (ECM). Their dysfunction can lead to cardiac diastolic or systolic dysfunction, and then heart failure. Galectin-3 and MMps act together on a variety of physiological and pathological processes in the human body. Many studies have shown that the expression of galectin-3 is positively correlated with matrix metalloproteinases 1, 2, and 9 in a variety of malignant tumors such as breast cancer and lung cancer, and they are jointly involved in the development of tumor diseases. Galectin-3 and MMP-9 work together to promote the metastasis of various tumors. The main mechanism is that Galectin-3 acts as a substrate of MMP-9. After being cleaved by MMP-9, Galectin-3 promotes the chemotaxis and migration of vascular endothelial cells by activating the pFAK pathway, thereby promoting the formation of new blood vessels. After vascular injury, both MMP-9 and Galectin-3 at the injured site increase.

[0007] Galectin-3 is widely expressed in human tissues, including various types of immune cells (macrophages, monocytes, dendritic cells, eosinophils, mast cells, natural killer cells, activated T and B cells), epithelial cells, endothelial cells, and sensory neurons. Galectin-3 is mainly located in the cytoplasm and shuttles into the nucleus. In addition, it is secreted to the cell surface and into biological fluids. The different locations of Galectin-3 contribute to its various functions. In the cytoplasm, Galectin-3 is important for cell survival due to its interaction with certain survival-related proteins, including B-cell lymphoma-2 (Bcl-2) and activated guanosine nucleotide (GTP)-bound K-Ras. In the nucleus, Galectin-3 promotes pre-mRNA splicing and regulates gene transcription, while extracellular Galectin-3 regulates cell-to-cell interactions, including those between epithelial cells and the extracellular matrix. Therefore, it is involved in cell differentiation, inflammation, fibrogenesis, and host defense. Therefore, Galectin-3 is crucial in many biological activities such as cell growth, apoptosis, pre-mRNA splicing, differentiation, transformation, angiogenesis, inflammation, fibrosis and host defense. Galectin-3 is involved in the pathogenesis of cardiovascular remodeling, as well as various autoimmune and inflammatory processes. Galectin-3 is closely related to the occurrence and development of many diseases and is a potential diagnostic marker and therapeutic target.

[0008] The content of Galectin-3 in body fluids such as blood or serum can reflect the disease status of the human body, such as chronic heart failure, so accurate quantification of Galectin-3 can be used to identify or predict diseases, to assess the severity of diseases, to stage or predict the consequences of diseases, or to monitor the effects of medications and other clinical or scientific research needs. So far, it is difficult to accurately quantify Galectin-3 and distinguish it from other galactose lectins or their protein fragments, because Galectin-3 and other 14 mammalian galactose lectins share a high degree of sequence similarity, especially in the conserved carbohydrate recognition domain (CRD); the CRD region of Galectin-3 can bind lactose, glycoproteins, laminin, etc. Another important factor is that Galectin-3 is a substrate of MMPs and can be cleaved by them, and the activity of Galectin-3 after cleavage is enhanced. Therefore, it is necessary to develop a detection method that can specifically measure the Galectin-3 level and distinguish between the Galectin-3 full-length protein and the Galectin-3 protein fragments cleaved by proteases without being affected by the CRD region binding to lactose, glycoproteins, laminin, etc.

[0009] Most of the current detection antibodies, detection methods or detection kits for Galectin-3 protein do not clearly state the range of Galectin-3 protein sites to be detected. Some detection methods or detection kits even use polyclonal antibodies, and it is impossible to determine whether the detection result is the Galectin-3 full-length protein content or the Galectin-3 total protein content. When using polyclonal antibodies, the detection result will be greater than the actual content of Galectin-3 protein in some detection methods. At present, except for the present invention, there are no other detection antibodies, detection methods or detection kits that exclude the influence of galactose, lactose, laminin, glycoprotein, ligand, etc. in the sample on the detection of Galectin-3 protein content. The detection results that do not exclude the influence of galactose, lactose, laminin, glycoprotein, ligand, etc. in the sample are controversial. Summary of the invention

[0010] In a first aspect, the present application provides an antibody or an antigen-binding portion thereof, wherein the antibody is capable of binding to human Galectin-3, and the binding epitope is located in the N-terminal 1-62 amino acid sequence region of human Galectin-3 as shown in SEQ ID NO:1.

[0011] In some embodiments, the antibody comprises HCDR1 shown in SEQ ID NO:3, HCDR2 shown in SEQ ID NO:4, HCDR3 shown in SEQ ID NO:5, LCDR1 shown in SEQ ID NO:6, LCDR2 shown in SEQ ID NO:7 and LCDR3 shown in SEQ ID NO:8, the antibody heavy chain variable region sequence is shown in SEQ ID NO:27, and the light chain variable region sequence is shown in SEQ ID NO:28.

[0012] In some embodiments, the antibody comprises HCDR1 shown in SEQ ID NO:9, HCDR2 shown in SEQ ID NO:10, HCDR3 shown in SEQ ID NO:11, LCDR1 shown in SEQ ID NO:12, LCDR2 shown in SEQ ID NO:13 and LCDR3 shown in SEQ ID NO:14, the antibody heavy chain variable region sequence is shown in SEQ ID NO:29, and the light chain variable region sequence is shown in SEQ ID NO:30.

[0013] In a second aspect, the present application provides an antibody or an antigen-binding portion thereof, wherein the antibody is capable of binding to human Galectin-3, and the binding epitope is located in the N-terminal 63-250 amino acid sequence region of human Galectin-3 as shown in SEQ ID NO:2.

[0014] In some embodiments, the antibody comprises HCDR1 shown in SEQ ID NO:15, HCDR2 shown in SEQ ID NO:16, HCDR3 shown in SEQ ID NO:17, LCDR1 shown in SEQ ID NO:18, LCDR2 shown in SEQ ID NO:19 and LCDR3 shown in SEQ ID NO:20, the antibody heavy chain variable region sequence is shown in SEQ ID NO:31, and the light chain variable region sequence is shown in SEQ ID NO:32.

[0015] In some embodiments, the antibody comprises HCDR1 shown in SEQ ID NO:21, HCDR2 shown in SEQ ID NO:22, HCDR3 shown in SEQ ID NO:23, LCDR1 shown in SEQ ID NO:24, LCDR2 shown in SEQ ID NO:25 and LCDR3 shown in SEQ ID NO:26, the antibody heavy chain variable region sequence is shown in SEQ ID NO:33, and the light chain variable region sequence is shown in SEQ ID NO:34.

[0016] In a third aspect, the present application provides an antibody combination product comprising a first antibody and a second antibody, wherein the first antibody and the second antibody are selected from the antibodies or antigen-binding portions thereof described in the first and second aspects.

[0017] In some embodiments, the first antibody is selected from the antibody or antigen binding portion thereof described in the first aspect and the second antibody is selected from the antibody or antigen binding portion thereof described in the second aspect.

[0018] In some embodiments, the first antibody is selected from the antibody or antigen binding portion thereof of the second aspect and the second antibody is selected from the antibody or antigen binding portion thereof of the first aspect.

[0019] In some embodiments, the first antibody and the second antibody are both selected from the antibodies or antigen-binding portions thereof described in the first aspect.

[0020] In some embodiments, the first antibody and the second antibody are both selected from the antibodies or antigen-binding portions thereof described in the second aspect.

[0021] In some embodiments, the first antibody is labeled with a detectable label.

[0022] In some embodiments, the second antibody is labeled with a detectable marker.

[0023] In some embodiments, the detectable label is selected from the group consisting of an enzyme, a prosthetic group, a fluorescent material, a luminescent material, a latex particle, a gold particle, a bioluminescent material, and a radioactive material.

[0024] In a fourth aspect, the present application provides a kit for detecting the level of galectin-3 in a sample from a human subject, comprising the antibody or antigen-binding portion thereof according to the first aspect and / or the second aspect or the antibody combination product according to the third aspect.

[0025] In some embodiments, the level of Galectin-3 is the level of human Galectin-3 full-length protein or the level of human Galectin-3 total protein.

[0026] In some embodiments, the level of Galectin-3 is the level of human Galectin-3 full-length protein.

[0027] In some embodiments, the level of Galectin-3 is the level of total human Galectin-3 protein.

[0028] In some embodiments, the kit uses a double antibody sandwich method to detect the level of galectin-3; the double antibody sandwich method is selected from ELISA, colloidal gold, immunochromatography, surface enhanced Raman scattering immunochromatography, chemiluminescence, microfluidics, and single molecule immunoarray. In some embodiments, the kit is an ELISA detection kit, a colloidal gold detection kit, an immunochromatography detection kit, a surface enhanced Raman scattering immunochromatography detection kit, a chemiluminescence detection kit, a microfluidics detection kit, and a single molecule immunoarray detection kit.

[0029] In a fifth aspect, the present application provides use of the antibody or antigen-binding portion thereof described in the first aspect and / or the second aspect or the antibody combination product described in the third aspect in the preparation of a kit for detecting the level of galectin-3 in a biological sample.

[0030] In a sixth aspect, the present application provides a use of the antibody or its antigen-binding portion described in the first aspect and / or the second aspect, or the antibody combination product described in the third aspect, in the preparation of a kit for diagnosing or assisting in the diagnosis of a disease, wherein the disease is selected from cardiovascular disease, tumor, rheumatic immune disease, kidney disease, respiratory system disease, digestive system disease or infectious disease.

[0031] In some embodiments, the cardiovascular disease is heart failure, coronary heart disease, or atrial fibrillation.

[0032] In some embodiments, the tumor is thyroid cancer, breast cancer, ovarian cancer, gastric cancer, esophageal cancer, non-small cell lung cancer, colon adenocarcinoma, or endometrial cancer.

[0033] In some embodiments, the rheumatic immune disease is rheumatoid arthritis.

[0034] In some embodiments, the kidney disease is chronic kidney disease.

[0035] In some embodiments, the respiratory disease is bronchial asthma, chronic obstructive pulmonary disease, or primary Sjögren's syndrome.

[0036] In some embodiments, the digestive disease is ulcerative colitis or cirrhosis of the liver.

[0037] In some embodiments, the infectious disease is sepsis.

[0038] In a seventh aspect, the present application provides a method for detecting the level of human Galectin-3, the method comprising:

[0039] Labeling the first antibody or the second antibody in the antibody combination product of the third aspect with a detectable marker;

[0040] The level of human Galectin-3 was detected using the double antibody sandwich method;

[0041] The double antibody sandwich method is selected from ELISA, colloidal gold, immunochromatography, surface enhanced Raman scattering immunochromatography, chemiluminescence, microfluidics, and single molecule immunoarray.

[0042] In some embodiments, the antibody or antigen-binding portion thereof of the first aspect is labeled with a detectable label.

[0043] In some embodiments, the antibody or antigen-binding portion thereof of the second aspect is labeled with a detectable label.

[0044] In some embodiments, the level of human Galectin-3 is the level of human Galectin-3 full-length protein or the level of human Galectin-3 total protein.

[0045] In some embodiments, the level of human Galectin-3 is the level of human Galectin-3 full-length protein.

[0046] In some embodiments, the level of human Galectin-3 is the level of total human Galectin-3 protein.

[0047] In some embodiments, the total protein level of human Galectin-3 is the sum of the full-length protein of human Galectin-3 and the Galectin-3 protein cleaved into fragments by proteases. Therefore, the total protein level of human Galectin-3 is the sum of the full-length protein of human Galectin-3 and the N-terminal amino acid fragment 63-250 of human Galectin-3, or the total protein level of human Galectin-3 is the sum of the full-length protein of human Galectin-3 and the N-terminal amino acid fragment 1-62 of human Galectin-3.

[0048] In some embodiments, the total human Galectin-3 protein level is the sum of the full-length human Galectin-3 protein and the N-terminal amino acid fragment of human Galectin-3 from position 63 to 250.

[0049] In some embodiments, the total human Galectin-3 protein level is the sum of the full-length human Galectin-3 protein and the N-terminal 1-62 amino acid fragment of human Galectin-3.

[0050] In some embodiments, the double antibody sandwich method is used to measure the level of human Galectin-3 protein, and one of the epitope antibodies within the amino acid range of positions 1-62 of the N-terminal protein of human Galectin-3 and the epitope antibodies within the amino acid range of positions 63-250 of the human Galectin-3 protein is used as a capture antibody, and the other antibody is used as a detection antibody.

[0051] In some embodiments, in the double antibody sandwich method, different epitope antibodies within the range of amino acids 1-62 at the N-terminus of human Galectin-3 protein are used as capture antibodies or detection antibodies.

[0052] In some embodiments, in the double antibody sandwich method, antibodies with different epitopes within the amino acid range of position 63-250 of human Galectin-3 protein are used as capture antibodies or detection antibodies.

[0053] In some embodiments, the antibody or antigen-binding portion thereof described in the first aspect or the second aspect binds to human Galectin-3 protein, and its binding is not affected by whether galactose, lactose, laminin, other glycoproteins or ligands bind to human Galectin-3 protein.

[0054] In some embodiments, the double antibody sandwich method includes but is not limited to ELISA, colloidal gold, immunochromatography, surface enhanced Raman scattering immunochromatography, chemiluminescence, microfluidics or single molecule immunoarray.

[0055] In some embodiments, the level of total human Galectin-3 protein can be detected using a sandwich method, a direct method, or an indirect method.

[0056] In an eighth aspect, the present application provides a method for diagnosing or assisting in the diagnosis of a disease, the method comprising:

[0057] Labeling the first antibody or the second antibody in the antibody combination product of claim 5 with a detectable marker;

[0058] Detecting the level of human Galectin-3 using a double antibody sandwich method, wherein the level of human Galectin-3 is the level of human Galectin-3 full-length protein or the level of human Galectin-3 total protein;

[0059] The double antibody sandwich method is selected from ELISA, colloidal gold, immunochromatography, surface enhanced Raman scattering immunochromatography, chemiluminescence, microfluidics, and single molecule immunoarray;

[0060] The disease is selected from cardiovascular disease, tumor, rheumatic immune disease, kidney disease, respiratory system disease, digestive system disease or infectious disease.

[0061] In some embodiments, the cardiovascular disease is heart failure, coronary heart disease, or atrial fibrillation.

[0062] In some embodiments, the tumor is thyroid cancer, breast cancer, ovarian cancer, gastric cancer, esophageal cancer, non-small cell lung cancer, colon adenocarcinoma, or endometrial cancer.

[0063] In some embodiments, the rheumatic immune disease is rheumatoid arthritis.

[0064] In some embodiments, the kidney disease is chronic kidney disease.

[0065] In some embodiments, the respiratory disease is bronchial asthma, chronic obstructive pulmonary disease, or primary Sjögren's syndrome.

[0066] In some embodiments, the digestive disease is ulcerative colitis or cirrhosis of the liver.

[0067] In some embodiments, the infectious disease is sepsis.

[0068] In some embodiments, the level of human Galectin-3 is the level of human Galectin-3 full-length protein or the level of human Galectin-3 total protein.

[0069] In some embodiments, the level of human Galectin-3 is the level of human Galectin-3 full-length protein.

[0070] In some embodiments, the level of human Galectin-3 is the level of total human Galectin-3 protein.

[0071] In some embodiments, the total human Galectin-3 protein level is the sum of the full-length human Galectin-3 protein and the Galectin-3 protein cleaved into fragments by protease.

[0072] In some embodiments, the total human Galectin-3 protein level is the sum of the full-length human Galectin-3 protein and the N-terminal amino acid fragment of human Galectin-3 from position 63 to 250.

[0073] In some embodiments, the total human Galectin-3 protein level is the sum of the full-length human Galectin-3 protein and the N-terminal 1-62 amino acid fragment of human Galectin-3. BRIEF DESCRIPTION OF THE DRAWINGS

[0074] Figure 1 Schematic diagram of the Galectin-3 protein structure.

[0075] Figure 2 The monoclonal antibody for Galectin-3 is affected by laminin.

[0076] Figure 3 ELISA standard curve for detecting Galectin-3 full-length protein using the antibody combination UV4E4-E15F10.

[0077] Figure 4 ELISA standard curve for detecting Galectin-3 total protein using antibody combination Q1E2-E15F10.

[0078] Figure 5 ELISA standard curve for the detection of total Galectin-3 protein by the antibody combination UV4E4–Y7E12.

[0079] Figure 6 Schematic diagram of the structure of Galectin-3 protein colloidal gold detection strip.

[0080] Figure 7 The standard curve for detecting the full-length Galectin-3 protein using the colloidal gold method using the antibody combination UV4E4-E15F10.

[0081] Figure 8 This is the standard curve for detecting Galectin-3 total protein using the colloidal gold method using the antibody combination Q1E2-E15F10.

[0082] Fig. 9The standard curve for detecting Galectin-3 total protein using the colloidal gold method with the antibody combination UV4E4–Y7E12.

[0083] Fig.10 Schematic diagram of the structure of Galectin-3 protein immunochromatographic detection strip.

[0084] Fig.11 The standard curve for detecting the full-length Galectin-3 protein using the antibody combination UV4E4-E15F10 immunochromatography.

[0085] Fig.12 The standard curve for detecting Galectin-3 total protein using the antibody combination Q1E2-E15F10 immunochromatography.

[0086] Fig.13 The standard curve for detecting Galectin-3 total protein by immunochromatography using the antibody combination UV4E4–Y7E12. DETAILED DESCRIPTION

[0087] The present invention provides a method for determining the level of human Galectin-3 full-length protein, the present invention provides a method for determining the level of human Galectin-3 total protein (including human Galectin-3 full-length protein and Galectin-3 protein cleaved into fragments by protease), the present invention relates to antibodies and antigen-binding fragments thereof that can specifically bind to human Galectin-3 in the detection method, the present invention relates to methods for using these antibodies and antigen-binding fragments thereof, and the present invention also relates to a kit containing the antibodies and antigen-binding fragments thereof.

[0088] The term "CDR" as used herein means a complementary determining region within an immunoglobulin variable region sequence. There are three CDRs in each of the variable regions of the heavy and light chains, which are designated as CDR1, CDR2, and CDR3 for each of the heavy and light chain variable regions. The term "CDR group" refers to a group of three CDRs that appear in a single variable region that is capable of binding to an antigen. The exact boundaries of these CDRs have been defined according to different systems. The system described by Kabat (Kabat et al. (1971) Ann. NY Acad. Sci. 190: 382-391; Kabat et al. (1987) Sequences of Proteins of Immunological Interest, Fourth Edition US Govt. Printing Off. No. 165-492; Kabat et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition. NIH Publication No. 91-3242) not only provides a clear residue numbering system that can be applied to any antibody variable region, but also provides precise residue boundaries that define the three CDRs. These CDRs may be referred to as Kabat CDRs. The amino acid residues in the CDR region are more variable (e.g., hypervariable) than other amino acid residues in the heavy and light chain variable regions of an antibody. Chothia and colleagues (Chothia and Lesk (1987) J. Mol. Biol. 196: 901-917; Chothia et al. (1989) Nature 342: 877-883) found that certain sub-portions within the Kabat CDRs adopt almost identical peptide backbone conformations, despite having great diversity at the amino acid sequence level. These sub-portions are designated as L1 (LCDR1), L2 (LCDR2), and L3 (LCDR3) or H1 (HCDR1), H2 (HCDR2), and H3 (HCDR3), where "L" and "H" designate light and heavy chain regions, respectively. These regions may be referred to as Chothia CDRs, which have borders that overlap with Kabat CDRs. Other boundaries defining CDRs that overlap with Kabat CDRs have been described by Padlan (1995) FASEB J. 9: 133-139 and MacCallum (1996) J. Mol. Biol. 262 (5): 732-45. Still other CDR boundary definitions may not strictly follow one of the systems herein, but still overlap with Kabat CDRs. The antibodies or antigen-binding portions thereof herein may utilize CDRs defined according to any of these systems.

[0089] Galectin-3

[0090] Galectin-3 (GenBank Accession Nos. NC_000014.9 (gene) and NP_002297.2 (protein)) is one of 15 mammalian β-galactoside-binding lectins or "galectins" that specifically bind to galactose. Galectin-3 is referred to in the literature as LGALS3, MAC-2 antigen, carbohydrate binding protein (CBP)-35, laminin binding protein, galactose-specific lectin 3, mL-34, L-29, hL-31, εBP, and IgE-binding protein.

[0091] Galectin-3 is the only member of the chimeric Gal, and has a collagen-like domain. Matrix metalloproteinases also have this structure. The similar structure makes Galectin-3 a substrate for matrix metalloproteinases, and it is easily degraded by matrix metalloproteinases, especially by MMP-2 or MMP-9. MMP-2 or MMP-9 degrades Galectin-3 at the Ala62-Tyr63 site, generating a 22kD fragment with a complete CRD and a 9kD polypeptide to form the amino terminus of Galectin-33. The CRD of the degraded 22kD fragment of Galectin-3 shows a higher affinity for carbohydrate ligands, which can enhance angiogenesis and is more likely to play a role in the metastasis and invasion of tumors. The closer Galectin-3 is to matrix cancer cells, the more invasive it will be.

[0092] Matrix metalloproteinases are endopeptidases that play a key role in the degradation of the extracellular matrix. Their dysfunction can lead to cardiac diastolic or systolic dysfunction, and then heart failure. Galectin-3 and MMps act together in a variety of physiological and pathological processes in the human body. Many studies have shown that the expression of galectin-3 and matrix metalloproteinases 1, 2, and 9 in a variety of malignant tumors such as breast cancer and lung cancer is positively correlated, and they are jointly involved in the development of tumor diseases.

[0093] The present invention discloses a method for determining the level of human Galectin-3 full-length protein. The present invention finds that the content of Galectin-3 full-length protein in a sample can be accurately determined by targeting the protein fragments at both ends of the human Galectin-3 protease cleavage site, namely Met1-Ala62 and Tyr63-Ile250. By using the antibodies disclosed herein and combining immunoassays known in the art, such as ELISA, immunochromatography, immunofluorescence, chemiluminescence, etc., the content of Galectin-3 full-length protein in a sample can be reliably and reproducibly detected.

[0094] The present invention discloses a method for determining the level of total human Galectin-3 protein. The present invention finds that by targeting the N-terminal fragment Met1-Ala62 or the Galectin-3 protein fragment with a CRD structure Tyr63-Ile250 produced after the human Galectin-3 protein is decomposed by an enzyme, the content of total Galectin-3 protein in the sample can be determined more accurately. By using the antibodies disclosed in this article and combining them with immunoassays known in the art, such as ELISA, immunochromatography, immunofluorescence, chemiluminescence, immunoturbidimetry, immunohistochemistry, Western Blot, etc., the total protein content of Galectin-3 in the sample can be reliably and reproducibly detected (including the full-length human Galectin-3 protein and the Galectin-3 protein cleaved into fragments by protease; for example, the total protein level of human Galectin-3 is the sum of the full-length human Galectin-3 protein and the N-terminal 63-250 amino acid fragment of human Galectin-3; for example, the total protein level of human Galectin-3 is the sum of the full-length human Galectin-3 protein and the N-terminal 1-62 amino acid fragment of human Galectin-3), which can more accurately evaluate the severity and staging of heart failure, cancer, inflammation, etc.

[0095] The method for determining the level of human Galectin-3 full-length protein in the present invention is used in combination with the method for determining the level of human Galectin-3 total protein, and can also analyze the levels of Galectin-3 full-length protein in the sample, Galectin-3 protein fragments with CRD structure produced after enzymatic decomposition, and their relationship with matrix metalloproteinases, as well as their association with diseases such as heart failure, cancer, and inflammation.

[0096] Biological functions of galectin-3

[0097] Galectin-3 has multiple biological functions. It can bind to multiple ligands on the cell surface and extracellular matrix and plays an important role in a series of physiological and pathological processes, including cell apoptosis, adhesion, proliferation, migration, inflammatory response, immune response and fibrosis.

[0098] 1. Promotes Inflammatory Response

[0099] Gatectin-3 is a pro-inflammatory factor that participates in acute, chronic, and allergic inflammatory processes and is a powerful inflammatory signal. It stimulates the activation and adhesion of neutrophils in acute inflammation and the activation of mononuclear macrophages and fibroblasts in chronic inflammation. Its pro-inflammatory effect is also manifested in inducing the release of inflammatory mediators from mast cells and chemotaxis of mononuclear macrophages, promoting macrophage migration, releasing mediators, and enhancing the effects of pro-inflammatory factors, which is different from the activation of macrophages caused by inflammatory mediators interferon in the traditional sense. Gatectin-3 can activate reduced coenzyme II, stimulate the production of superoxide in neutrophils, mediate the production of interleukin IL-4 caused by lipopolysaccharide, and promote chemotaxis of monocytes. IL-4 can act on macrophages to stimulate the expression and secretion of Galectin-3, and selectively bind 4 to stimulate the activation of other phenotypes of macrophages. The activation of macrophages by IL-4 can be inhibited by disulfide, which is a carbon-hydrogen bond inhibitor of extracellular Galectin-3. Therefore, when extracellular Galectin-3 is over-secreted, the antibody may negatively feedback to macrophages through disulfirane, reducing excessive macrophage activation. It is predicted that Gatectin-3 is a regulatory molecule in different stages of the process from acute inflammation to chronic inflammatory fibrosis.

[0100] 2. Promote fibrosis

[0101] Various neuroendocrine hormones in the body can activate macrophages, which can secrete Galectin-3 and directly induce the activation of fibroblasts and the deposition of type I collagen in the extracellular matrix. When tissue damage occurs, Galectin-3 is secreted into the extracellular space to activate cyclin D1, causing the proliferation of cytoskeletal proteins and type I collagen α-i chains in the extracellular matrix, thereby activating quiescent fibroblasts and leading to myofibrosis. The irreversible interaction of type I collagen becomes the main mitogen, stimulating the proliferation and collagen synthesis of myofibroblasts through lectin carbohydrate interactions. The extracellular matrix is ​​an interconnected complex three-cell network-like spatial structure, mainly formed by collagen and fibronectin. Type I collagen and type III collagen play an important role in maintaining the normal structure of the heart and the conduction of the myocardium, and maintaining the coordination of myocardial contraction and relaxation. Type I collagen is a stiff fibrous protein, and type III collagen is an elastic protein. Studies have shown that Galectin-3 is involved in the fibrosis process of the liver, blood vessels, kidneys, lungs, and heart.

[0102] 3. Modulate immune response

[0103] Galectin-3 is mainly involved in nonspecific immunity and is expressed in a variety of immune cells, including dendritic cells, natural killer cells, activated T cells, and B cells. In activated primitive T cells, it promotes the growth of type 1 helper T cells, restricts the differentiation of type 2 helper T cells and regulatory T cells, and mediates immune responses. Application of Galectin-3 in disease diagnosis

[0104] 1. Application of Galectin-3 in the diagnosis of cardiovascular diseases

[0105] 1.1Galectin-3 and heart failure

[0106] Heart failure (HF) is the terminal stage and the main cause of death of various cardiovascular diseases. It is a more complex clinical syndrome. With the increase in the number of elderly people and the extension of the survival of heart disease patients by modern treatment, the incidence of HF is gradually increasing. Galectin-3 is expressed before heart failure occurs, so it is very useful for predicting and preventing the progression of the disease. In the United States, Galectin-3 has been approved as an indicator for judging the prognosis of patients with heart failure and has been used in clinical practice. Studies have found that patients with acute heart failure with high levels of Galectin-3 have a higher incidence of adverse cardiovascular events within 30 days. In addition, Galectin-3 levels may be positively correlated with the mortality rate of patients with heart failure, and have greater prognostic value for patients with heart failure with normal left ventricular ejection fraction than for patients with heart failure with decreased left ventricular ejection fraction. Doubled Galectin-3 levels are significantly associated with the hospitalization rate and mortality rate of patients with heart failure. The study found that regardless of clinical symptoms, signs and laboratory test results, Galectin-3 levels > 25.9 ng / mL were a precursor to rapid progression of heart failure, hospitalization and death.

[0107] The level of Galectin-3 is closely related to myocardial fibrosis, and its concentration is proportional to the degree of myocardial fibrosis. Galectin-3 promotes myocardial fibrosis and participates in myocardial inflammatory changes and ventricular remodeling. Studies have found that Galectin-3 levels are associated with the mortality of patients with acute and chronic heart failure, and can be used to assess the prognosis of patients with chronic heart failure and predict new heart failure. Galectin-3 can be used as an indicator of the progression of heart failure and the prognosis of heart failure. The degree of progression of heart failure can be judged according to the degree of its increase, so that early intervention can be carried out to prevent the patient's condition from worsening, thereby reducing long-term mortality.

[0108] 1.2Galectin-3 and coronary heart disease

[0109] Coronary heart disease, also known as coronary atherosclerotic heart disease (CHD), is a heart disease caused by atherosclerotic lesions in the coronary arteries, which causes stenosis or obstruction of the vascular lumen, resulting in myocardial ischemia, hypoxia or necrosis. Studies have found that compared with the healthy group, the plasma levels of Galectin-3, MMP-9 and MMP-3 in patients with coronary heart disease were significantly increased, and were related to the degree of lesions. The mechanism of Galectin-3 causing atherosclerosis also includes the following: ① Participating in the phenotypic transformation, proliferation, migration and secretion of matrix by oxidized low-density lipoprotein-induced vascular smooth muscle cells, increasing the ability of vascular endothelial cells and macrophages to absorb lipids, and accelerating the formation of atherosclerotic plaques; ② Chemotaxis of monocytes, aggregation of macrophages, and acceleration of the formation of foam cells; ③ Stimulating the production of superoxide by neutrophils and enhancing oxidative stress response. Patients with coronary heart disease with high Galectin-3 levels have a higher cardiovascular mortality rate. Galectin-3 is an independent risk factor for cardiovascular death and all-cause death in the general population. Serum MMP-9, MMP-3 and Galectin-3 detection in CHD patients can timely assess the condition and provide treatment, which helps to improve the prognosis and reduce the occurrence of major adverse cardiovascular events (MACE).

[0110] 1.3Galectin-3 and atrial fibrillation

[0111] Atrial fibrillation is a common rapid arrhythmia. Studies have shown that the presence of atrial fibrillation is significantly associated with increased morbidity and mortality from cardiovascular diseases. The mechanism of atrial fibrillation is not very clear. The current main view is that atrial fibrillation occurs due to atrial electrical and structural remodeling caused by inflammation and fibrosis. Galectin-3 is one of the molecules involved in inflammation and fibrosis. Studies have shown that it can promote cardiac macrophage infiltration and stimulate myofibroblast proliferation, thereby causing atrial fibrosis and playing a role in the occurrence of atrial fibrillation. Elevated plasma Galectin-3 levels increase the risk of atrial fibrillation. In addition, Galectin-3 is also associated with the recurrence of atrial fibrillation. Galectin-3 plays an important role in the occurrence and progression of atrial fibrillation, and is expected to become a biochemical marker for the diagnosis of atrial fibrillation.

[0112] 2. Application of Galectin-3 in tumor diagnosis

[0113] Galectin-3 participates in angiogenesis, increases the aggregation of tumor cells and their adhesion to vascular endothelial cells to promote tumor metastasis, and is closely related to the occurrence and development of tumors. It has a great correlation with the occurrence and development of various tumors, such as lung cancer, breast cancer, thyroid cancer, pancreatic cancer, etc. Many studies have shown that Galectin-3 can be used as an indicator to predict the diagnosis and prognosis of cancer.

[0114] 2.1Galectin-3 and thyroid cancer

[0115] Thyroid cancer is the most common tumor in the endocrine system. Galectin-3 is not expressed in normal thyroid tissue, and is expressed in small amounts in benign thyroid tumors. However, it is expressed at a higher rate in malignant thyroid cancer. Galectin-3 is positively correlated with the malignancy of thyroid cancer. Papillary thyroid carcinoma (PTC) is one of the more common malignant tumors in the endocrine system, accounting for about 65% of primary thyroid malignant tumors. Galectin-3 is expressed in papillary thyroid carcinoma (PTC) and has an important relationship with the development and deterioration of PTC. Galectin-3 can be used as an indicator for indeterminate cytology examination of thyroid cancer, and has been clinically verified and used in many countries and regions.

[0116] 2.2Galectin-3 and breast cancer

[0117] Breast cancer is a phenomenon in which mammary epithelial cells proliferate uncontrollably under the influence of multiple carcinogens. Studies have found that the absorption of Galectin-3 is extremely important in cell proliferation. It can regulate the adhesion and spread of cancer cells during the progression of breast cancer. This regulatory effect is very powerful. After inhibiting the expression of Galectin-3 in thyroid papillary carcinoma cell lines, the proliferation rate of tumor cells decreased. After blocking the expression of Galectin-3 in a nude mouse breast cancer model, the proliferation of tumor cells decreased.

[0118] 2.3Galectin-3 and ovarian cancer

[0119] Ovarian cancer is a type of malignant tumor of the ovary, which refers to a malignant tumor that grows on the ovary. 90% to 95% of these tumors are primary ovarian cancers, and the remaining 5% to 10% are primary cancers that metastasize to the ovary from other parts of the body. Since ovarian cancer lacks symptoms in the early stages, and even if there are symptoms, they are not specific, and the role of screening is limited, early diagnosis is difficult. When 60% to 70% of patients seek medical treatment, they are already in the advanced stage, and the treatment efficacy of advanced cases is poor. Galectin-3 is highly expressed in ovarian cancer and is associated with the patient's progression-free survival (PFS) [3]. Compared with normal ovarian tissue, Galectin-3 is highly expressed in epithelial ovarian cancer tissue and is associated with clinical stage. The later the stage, the higher the expression level of Galectin-3. There is also a difference in Galectin-3 expression between early (stage I-II) and late (stage III-IV) patients. It is speculated that Galectin-3 may be involved in the occurrence and development of ovarian cancer, and may be used as an indicator for clinically judging the degree of benign or malignant epithelial ovarian tumors, which helps to predict the occurrence, development, treatment effect and prognosis of ovarian tumors.

[0120] 2.4Galectin-3 and Gastric Cancer

[0121] Gastric cancer is the most common malignant tumor in the digestive tract. The average expression level of Galectin-3 mRNA in gastric cancer, peritoneal metastasis and lymph node metastasis is significantly higher than that in non-cancerous mucosa. In gastric cancer, the expression of Galectin-3 is positively correlated with its differentiation degree and tumor metastasis.

[0122] 2.5Galectin-3 and other cancers

[0123] Overexpression of Galectin-3 in esophageal cancer significantly enhances the proliferation and invasion of cancer cells, and significantly inhibits cell apoptosis. Galectin-3 is widely expressed in non-small cell lung cancer (NSCLC) tissues and is correlated with the stage. High expression of Galectin-3 is significantly correlated with the occurrence, development, invasion, and poor differentiation of colon adenocarcinoma. Galectin-3 expression is closely related to endometrial diseases such as endometriosis and endometrial cancer.

[0124] 3.Galectin-3 and rheumatic immune diseases

[0125] Rheumatoid arthritis is an autoimmune disease with disordered immune function and imbalance of various cytokines, which leads to inflammation, cartilage invasion and bone damage. Galectin-3 is closely related to rheumatoid arthritis. Studies have shown that in addition to chronic infiltration of inflammatory cells, fibroblasts also play an important role in rheumatoid arthritis. If fibroblasts accumulate too much in the synovial tissue, the joint structure will also be destroyed. Studies have shown that Galectin-3 is more prominent in inducing CCL2, CCL3, CCL5 and TNF-α in synovial tissue, proving that Galectin-3 can promote the secretion of proinflammatory cytokines by tissue fibroblasts and has an inducing stimulating effect in the onset of rheumatoid arthritis.

[0126] 4.Galectin-3 and kidney disease

[0127] Chronic kidney disease (CKD) has become a global public health problem with high morbidity and mortality. One of the characteristics of CKD is chronic renal fibrosis. The end result is excessive deposition of a large amount of extracellular matrix, including sugars and proteins or proteoglycans. The main mediator of renal fibrosis is macrophages, which can stimulate the production of activation factors, activate a large number of extracellular matrix-secreting fibroblasts, and some fibroblasts can secrete cytokines, which further induce the formation of extracellular matrix and deposit in the kidneys. The role of Galectin-3 in fibrosis is related to macrophages. Macrophages are divided into M1 and M2 types. M1 is the main component of inflammation and immune damage; M2 plays an important role in promoting angiogenesis, cell proliferation and extracellular matrix remodeling. Galectin-3 can chemotactic mononuclear macrophage infiltration, selectively activate M2 macrophages, and then secrete a variety of cytokines, produce a large number of fibroblasts to cause fibrosis. In summary, it can be seen that Galectin-3 is closely related to renal fibrosis. For CKD, some scholars have also shown that Galectin-3 can reduce tubular cell apoptosis and renal damage, thereby delaying the development of CKD. Galectin-3 may play an important role in the early occurrence and development of CKD.

[0128] 5.Galectin-3 and respiratory diseases

[0129] A large number of studies have shown that Galectin-3 is closely related to bronchial asthma in respiratory diseases. Bronchial asthma is a chronic inflammatory disease of the airways involving multiple cells and cell components (including mast cells, eosinophils, T lymphocytes, etc.), and usually reversible airflow limitation occurs. Galectin-3 plays a key role in the recruitment of eosinophils and allergic airway inflammation in vivo. Galectin-3 can act as a cell surface adhesion molecule to make eosinophils roll and adhere to endothelial cells, and play a role in the aggregation and transportation of eosinophils, thereby releasing inflammatory factors to induce asthma attacks. Zuberi et al. used ovalbumin to induce asthma attacks in mice and found that the expression of eosinophils in Galectin-3 gene-deficient mice was less than that in wild-type mice without knockout genes, and Galectin-3 may control asthma attacks by regulating Th1 cells and Th2 cells. López et al. used the Galectin-3 gene method to treat asthma rat models, and the results showed that eosinophils decreased and airway hyperresponsiveness was reduced. This provides a new idea for the clinical treatment of refractory asthma.

[0130] Chronic obstructive pulmonary disease (COPD) is a common preventable and treatable disease characterized by persistent airflow limitation. The progressive airflow limitation is associated with an enhanced chronic inflammatory response of the airways and lungs to toxic particles or gases. Studies have found that compared with healthy people, serum Galectin-3 levels in COPD patients are significantly increased. Increased serum and lung tissue Galectin-3 levels in patients with severe COPD are associated with endothelial damage and increased airway obstruction. In addition to inflammation in the lungs themselves, COPD patients usually present with a systemic inflammatory state, and acute exacerbation of COPD can lead to an increased mortality rate of the disease. Serum Galectin-3 levels during acute exacerbation are significantly higher than those during remission. Galectin-3 is a valuable indicator for predicting acute exacerbation of COPD.

[0131] Primary Sjögren's syndrome (PPS) is mainly caused by the suppression of T cell function, and B cells produce a large amount of antibodies to induce tissue damage, among which the lungs are most commonly affected, resulting in pulmonary interstitial fibrosis. Galectin-3 can regulate fibroblast activation and is related to PPS and the occurrence of pulmonary interstitial fibrosis. The expression level of Galectin-3 in PPS patients is significantly higher than that in normal controls, and the expression level of Galectin-3 in patients with pulmonary interstitial fibrosis is more prominent. It is speculated that Galectin-3 may be involved in the immune inflammatory damage of PPS and the occurrence and development of pulmonary interstitial fibrosis.

[0132] 6.Galectin-3 and digestive system diseases

[0133] Ulcerative colitis (UC) is a chronic nonspecific inflammatory disease that mainly invades the colonic mucosa. Cell apoptosis plays an important role in the pathogenesis of UC. Bcl-2 is an inhibitory gene for cell apoptosis. Galectin-3 is similar to the Bcl-2 gene in structure and contains four amino acid combinations that are the same as the Bcl-2 gene. These combinations are the important amino acid sequences that inhibit apoptosis. It is speculated that the activation of Galectin-3 can also inhibit cell apoptosis. Normal colorectal mucosal epithelial cells can strongly express Galectin-3, but in UC patients, the expression level is significantly reduced, and this expression is negatively correlated with the severity of UC lesions. Bcl-2 is also expressed in normal colorectal mucosal epithelial cells, but unlike Galectin-3, in UC patients, the Bcl-2 gene is increased. It is speculated that it may be a reactive hyperplasia to cell damage, with an increase in inflammatory cells and a slowing of cell apoptosis. However, both suggest that they can play an important role in UC patients.

[0134] Cirrhosis is diffuse liver damage caused by the long-term or repeated effects of one or more causes. Galectin-3 is involved in many physiological and pathological processes in the body, including cell growth, cell adhesion, inflammatory response, immune regulation, tumor transformation and metastasis, and cell apoptosis. As mentioned earlier, Galectin-3 can participate in the formation of fibrosis in organs such as the kidneys, lungs, and liver. Experiments have also confirmed that Galectin-3 can promote the proliferation of hepatic stellate cells through the MEK1 / 2-ERK1 / 2 signaling pathway, thereby promoting the formation of cirrhosis. Compared with wild-type Galectin-3 gene non-knockout mice, although the same risk factors exist in Galectin-3 gene knockout mice, the damage to cirrhosis in wild-type mice is much more severe.

[0135] 7.Galectin-3 and infectious diseases

[0136] Sepsis is a type of disease caused by uncontrolled inflammatory response, which is essentially a systemic inflammatory response syndrome. Galectin-3 plays an important role in many aspects of inflammatory response, including macrophage-mediated bacterial phagocytosis and phagosome maturation, activating actin polymerization to promote bacterial internalization, and regulating the expression of vesicle transport regulatory proteins and lysosomal enzymes to affect phagolysosomal fusion and bacterial killing. The research shows the role and mechanism of Galectin-3 in the interaction between macrophages and pathogenic microorganisms, providing a new theoretical basis for further improving the treatment of sepsis.

[0137] In summary, Galectin-3 is widely expressed in human tissues, including various types of immune cells, epithelial cells, endothelial cells and sensory neurons, and is distributed in the cytoplasm, nucleus, cell surface and body fluids. Galectin-3 plays an important role in a series of physiological and pathological processes, including cell apoptosis, adhesion, proliferation, migration, inflammatory response, immune response and fibrosis. Galectin-3 has been shown to be an indicator of the progression and prognosis of heart failure in cardiovascular diseases. In the diagnosis and treatment of cancer, Galectin-3 has also been shown to be a possible indicator for clinically judging the degree of benign and malignant tumors, which helps predict the occurrence, development, treatment effect and prognosis of tumors. In addition, Galectin-3 is also related to rheumatoid arthritis, kidney and lung fibrosis, inflammatory response and so on.

[0138] Antibodies and antigen-binding fragments thereof

[0139] The present invention provides antibodies and antigen-binding fragments thereof that bind to human Galectin-3 protein. The binding sites of the provided antibodies and antigen-binding fragments thereof are within the range of amino acids 1 to 62 at the N-terminus of the human Galectin-3 protein. The provided antibodies and antigen-binding fragments thereof do not compete with galactose, lactose, laminin, other glycoproteins or ligands for binding to human Galectin-3 protein, that is, the binding of the provided antibodies and antigen-binding fragments thereof to human Galectin-3 protein is not affected by whether galactose, lactose, laminin, other glycoproteins or ligands bind to human Galectin-3 protein.

[0140] The N-terminal fragment of the human Galectin-3 protein in this article after being decomposed by enzyme contains a 62 amino acid sequence of amino acids 1 to 62, as follows: MADNFSLHDALSGSGNPNPQ GWPGAWGNQP AGAGGYPGAS YPGAYPGQAP PGAYPGQAPPGA. (SEQ ID NO.1)

[0141] The present invention also provides antibodies and antigen-binding fragments thereof that bind to human Galectin-3 protein. The provided antibodies and antigen-binding fragments thereof bind to different epitopes of Galectin-3 protein fragments with complete CRD after human Galectin-3 protein is decomposed by enzymes. The provided antibodies and antigen-binding fragments thereof bind to different epitopes of human Galectin-3 protein fragments or human Galectin-3 protein. The provided antibodies and antigen-binding fragments thereof do not compete with galactose, lactose, laminin, other glycoproteins or ligands for binding to human Galectin-3 protein fragments or human Galectin-3 protein, that is, the provided antibodies and antigen-binding fragments thereof bind to human Galectin-3 protein fragments or human Galectin-3 protein without being affected by whether galactose, lactose, laminin, other glycoproteins or ligands bind to human Galectin-3 protein fragments or human Galectin-3 protein.

[0142] Competitive binding in this article means that the binding of one antibody or antibody fragment to the antigen reduces the binding of the second antibody or antibody fragment to the same antigen, or the binding of one antibody or antibody fragment to the antigen reduces the binding of galactose, lactose, laminin, other glycoproteins or ligands to the same antigen, or the binding of galactose, lactose, laminin, other glycoproteins or ligands to the antigen reduces the binding of one antibody or antibody fragment to the same antigen.

[0143] The enzymatically decomposed Galectin-3 protein fragment with complete CRD herein contains the 188 amino acid sequence of amino acids 63-250 of human Galectin-3, as follows: YPGAPGAY PGAPAPGVYP GPPSGPGAYPSSGQPSATGAYPATGPYGAP AGPLIVPYNL PLPGGVVPRM LITILGTVKP NANRIALDFQ RGNDVAFHFNPRFNENNRRV IVCNTKLDNN WGREERQSVF PFESGKPFKIQVLVEPDHFK VAVNDAHLLQ YNHRVKKLNEISKLGISGDIDLTSASYTMI. (SEQ ID NO.2)

[0144] In some embodiments, the antibody is a monoclonal antibody and the antigen-binding fragment is derived from the monoclonal antibody, which can be prepared using techniques widely used in the art (including hybridoma, recombinant antibodies, phage display, single B cell technology, or a combination thereof).

[0145] Anti-human Galectin-3 monoclonal antibodies can be prepared using any known techniques, including hybridoma technology, in which mice, rats, hamsters, chickens, rabbits or other suitable experimental animals are immunized with an immunizing agent to elicit lymphocytes that are capable of expressing antibodies that specifically bind to the immunizing antigen.

[0146] The immunizing agent usually includes an adjuvant and an antigen, and the adjuvant is usually Freund's adjuvant or other suitable adjuvants. The antigen used in the present invention is a full-length recombinant protein of human Galectin-3, or a recombinant protein of amino acids 1-62 of the N-terminal protein of human Galectin-3, or a polypeptide of any part of amino acids 1-62 of the N-terminal protein of human Galectin-3, or a recombinant protein of amino acids 63-250 of human Galectin-3, or a polypeptide of any part of amino acids 63-250 of human Galectin-3. The polypeptide needs to be coupled with a carrier protein, and the carrier protein can be KLH (Keyhole Limpet Hemocyanin), BSA (Bovine Serum Albumin) or OVA (Ovalbumin). Animals can be immunized with or without adjuvants in various ways. The immunizing agent can be used for immunization only once or multiple times, and the immunization site can be subcutaneous, intramuscular, intraperitoneal or intravenous injection.

[0147] The acquisition of hybridomas uses a fusion agent such as polyethylene glycol or an electric fusion instrument to fuse lymphocytes with immortal cell lines. Immortal cell lines usually use mouse or rat myeloma cell lines. For example, SP2 / 0 cells that lack hypoxanthine-guanine-phosphoribosyltransferase and cannot synthesize DNA using the salvage pathway are used. HAT medium is used for screening and culture, and only fused hybridoma cells survive and proliferate. Hybridoma cells are screened by enzyme-linked immunosorbent assay (ELISA) using screening antigens.

[0148] In some embodiments, the screening antigen is a full-length Galectin-3 protein, or a recombinant protein of amino acids 1-62 of the N-terminal protein of human Galectin-3, or a polypeptide of any part of amino acids 1-62 of the N-terminal protein of human Galectin-3, or a recombinant protein of amino acids 63-250 of human Galectin-3, or a polypeptide of any part of amino acids 63-250 of human Galectin-3, lactose, laminin, etc., or several of them. The screening method is indirect ELISA, double antibody sandwich ELISA or competitive ELISA, etc.

[0149] In some embodiments, the antibodies or fragments described herein comprise the heavy and / or light chains (or fragments thereof) of antibodies produced by hybridomas of the present invention. In some embodiments, the antibodies or fragments described herein comprise the heavy and / or light chain variable regions (or fragments thereof) of antibodies produced by hybridomas of the present invention. As known in the art, the specificity of an antibody to a given antigen is mediated by the heavy and light chain variable regions. Specifically, the specificity of an antibody to a given antigen is primarily determined by short sequences within the heavy and light chain variable regions known as complementary determining regions or CDRs. In some embodiments, the antibodies or fragments described herein contain one or more (e.g., one, two, three, four, five, or six) CDRs of the heavy and / or light chains of antibodies produced by hybridomas of the present invention. In some embodiments, the antibodies or fragments described herein comprise each CDR of the heavy chain of an antibody produced by a hybridoma of the present invention. In some embodiments, the antibodies or fragments described herein comprise each CDR of the light chain of an antibody produced by a hybridoma of the present invention. In some embodiments, the antibodies or fragments described herein comprise each CDR of the light chain of an antibody produced by a hybridoma of the present invention (all heavy and light chain CDRs).

[0150] The "variable region" or "variable domain" of an antibody refers to the amino-terminal domain of the heavy or light chain of an antibody. The variable domain of the heavy chain may be referred to as "VH". The variable domain of the light chain may be referred to as "VL". These domains are generally the most variable parts of the antibody and contain the antigen binding site. The light or heavy chain variable region (VL or VH) consists of a framework region interrupted by three hypervariable regions called "complementarity determining regions" or "CDRs". The framework region of an antibody, i.e., the combined framework region of the constituent light and heavy chains, serves to position and align the CDRs, which are primarily responsible for binding to the antigen.

[0151] As used herein, "skeleton", "framework" or "FR" regions mean regions of antibody variable domains excluding those regions defined as CDRs. Each antibody variable domain framework can be further subdivided into adjacent regions (FR1, FR2, FR3 and FR4) separated by CDRs. Typically, the variable regions VL / VH of the heavy and light chains can be obtained by connecting the following numbered CDRs and FRs in the following combinations: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.

[0152] In some embodiments, the antibodies or fragments described herein are chimeric in that they contain at least one human constant region. For example, the constant region of the antibody produced by the hybridoma of the present invention can be replaced with a human constant region. Chimeric antibodies are generally less immunogenic to humans than non-chimeric antibodies, and therefore may provide therapeutic advantages in certain situations. In some embodiments, the chimeric antibodies described herein contain an IgG1 constant region. Various human constant regions are known to those skilled in the art. Methods for preparing chimeric antibodies are known in the art.

[0153] In some embodiments, the antibodies or fragments described herein are humanized in that they comprise at least one human framework region. For example, one or more (e.g., one, two, three, four, five, or six) framework regions of an antibody produced by a hybridoma of the invention may be replaced with one or more (e.g., one, two, three, four, five, or six) human framework regions. Humanized antibodies are generally less immunogenic to humans than non-humanized antibodies, and therefore may provide therapeutic advantages in certain situations. Various human framework regions are known to those skilled in the art. Methods for preparing humanized antibodies are known in the art.

[0154] In some embodiments, the antigen binding fragment is derived from a complete antibody molecule, such as a monoclonal antibody. The antibody may be a F(ab')2 fragment produced at the carboxyl end of its hinge region, or a Fab fragment produced at the amino end of its hinge region. In some embodiments, the antigen binding fragment is a Fab fragment, a F(ab')2 fragment, a scFv fragment, a linear antibody, a multispecific antibody fragment, such as a bispecific, trispecific or multispecific antibody (e.g., a dimer, a trimer or a tetramer), a mini antibody, a chelated recombinant antibody, an intrabody, a nanobody, a small modular immune drug (SMIP), a binding domain immunoglobulin fusion protein, a camelized antibody or an antibody containing VHH. The preparation method is known in the art.

[0155] In some embodiments, the antibodies or antigen-binding antibody fragments described herein comprise one or more substitutions, deletions or insertions of amino acids compared to the heavy and / or light chains of the antibodies produced by the hybridomas of the present invention. Substitutions, deletions or insertions can be introduced into nucleic acid molecules encoding the heavy and / or light chains of the antibodies produced by the hybridomas of the present invention by conventional techniques such as site-directed mutagenesis or PCR-mediated mutagenesis. In some embodiments, conservative amino acid substitutions are made at one or more sites. "Conservative amino acid substitutions" are situations in which one amino acid residue is replaced by an amino acid residue with a similar side chain. Families of amino acids with similar side chains have been defined in the art, and include basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).

[0156] Monoclonal antibodies can also be produced by recombinant DNA methods known in the art. Monoclonal antibodies can also be produced by phage display libraries known in the art.

[0157] Methods of using antibodies and antigen-binding fragments thereof

[0158] Method for determining Galectin-3 protein level in human body fluid samples

[0159] The present invention provides a method for determining the level of Galectin-3 protein in a human body fluid sample, wherein the method is to detect the content of Galectin-3 full-length protein in the sample by a sandwich method, or to detect the content of Galectin-3 total protein in the sample by a sandwich method. In some embodiments, the body fluid sample is blood, serum, plasma, urine, cerebrospinal fluid, ascites, bile, gastric juice, saliva, sweat, tissue exudate, tissue cell lysate, etc.

[0160] In some embodiments, the sandwich method for detecting the content of Galectin-3 full-length protein in the sample uses at least two (e.g., two, three or four) antibodies or antibody fragments described in the present invention to determine the level of human Galectin-3 full-length protein in the sample. In some embodiments, the sandwich method for detecting the content of Galectin-3 full-length protein in the sample uses an epitope antibody within the amino acid range of positions 1-62 of the N-terminal protein of human Galectin-3 as a capture antibody, and an epitope antibody within the amino acid range of positions 63-250 of the human Galectin-3 protein as a detection antibody. In some embodiments, the sandwich method for detecting the content of Galectin-3 full-length protein in the sample uses an epitope antibody within the amino acid range of positions 63-250 of the human Galectin-3 protein as a capture antibody, and an epitope antibody within the amino acid range of positions 1-62 of the N-terminal protein of human Galectin-3 as a detection antibody.

[0161] In some embodiments, the sandwich method for detecting the total protein content of Galectin-3 in the sample uses at least two (e.g., two, three or four) antibodies or antibody fragments described in the present invention to determine the level of total human Galectin-3 protein in the sample. In some embodiments, the sandwich method for detecting the total protein content of Galectin-3 in the sample uses antibodies with different epitopes within the amino acid range of positions 1-62 of the human Galectin-3 protein as capture antibodies and detection antibodies, respectively. In some embodiments, the sandwich method for detecting the total protein content of Galectin-3 in the sample uses antibodies with different epitopes within the amino acid range of positions 63-250 of the human Galectin-3 protein as capture antibodies and detection antibodies, respectively.

[0162] In some embodiments, the capture conjugate is contacted with the sample to be tested and binds to the Galectin-3 protein or Galectin-3 protein fragment therein, and then contacts and binds to the detection antibody. In this embodiment, the capture conjugate and the detection antibody bind to different binding epitopes on the Galectin-3 protein or Galectin-3 protein fragment, respectively, and are not affected by whether the Galectin-3 protein fragment or Galectin-3 protein binds to galactose, lactose, laminin, other glycoproteins or ligands.

[0163] The capture conjugate herein refers to a method for separating Galectin-3 protein or Galectin-3 protein fragments from a mixture of samples to be tested. In some embodiments, the capture conjugate portion may be a Galectin-3 monoclonal antibody, but is not limited thereto, and may also be a Galectin-3 polyclonal antibody, or may be laminin, or may be lactose or other molecules that can bind to Galectin-3 protein or Galectin-3 protein fragments. The capture conjugate portion is covalently or non-covalently bonded to a microplate, a membrane, a magnetic particle, a latex particle, a test tube, a small tank, a chip or other reactor or support.

[0164] The detection antibody herein refers to an antibody and its antigen-binding fragment that can be labeled with a detectable marker, including but not limited to various enzymes, prosthetic groups, fluorescent substances, luminescent substances, latex particles, gold particles, bioluminescent substances and radioactive substances. In some embodiments, suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, acetylcholinesterase, malate dehydrogenase, staphylococcal nuclease, δ-V-steroid isomerase, yeast alcohol dehydrogenase, α-glycerophosphate dehydrogenase, triosephosphate isomerase, asparaginase, glucose oxidase, ribonuclease, urease, glucose-6-phosphate dehydrogenase, glucoamylase; in some embodiments, suitable prosthetic group complexes include streptavidin, biotin avidin, biotin; in some embodiments, Suitable fluorescent substances include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylaminofluorescein, dansyl chloride, quantum dots or phycoerythrin, phycocyanin, allophycocyanin, o-phthalaldehyde and fluorescamine; in some embodiments, luminescent substances include luminol, AMPPD, etc.; in some embodiments, bioluminescent substances include luciferase, luciferin and aequorin; in some embodiments, suitable radioactive substances include 125I, 131l, 35S, 14C or 3H.

[0165] In some embodiments, the sandwich method uses an enzyme-linked immunosorbent assay (ELISA), which is a technique for detecting and measuring the concentration of an antigen using a labeled (e.g., enzyme-linked) form of an antibody. In a sandwich ELISA, a capture substance (e.g., an antibody) is linked to a solid phase (i.e., a microplate) and contacted with a biological sample containing an antigen, and then the solid phase is washed to remove unbound antigens and other substances, and then a labeled antibody (e.g., an enzyme-linked antibody) is bound to the antigen that has been bound to the capture antibody, thereby forming a capture antibody-antigen-labeled antibody sandwich, and the enzyme that can be linked to the antibody can be horseradish peroxidase, alkaline phosphatase, β-galactosidase, acetylcholinesterase, malate dehydrogenase, staphylococcal nuclease, δ-V-steroid isomerase, yeast alcohol dehydrogenase, α-glycerophosphate dehydrogenase, triosephosphate isomerase, asparaginase, glucose oxidase, ribonuclease, urease, glucose-6-phosphate dehydrogenase, glucoamylase, and the enzyme-linked antibody reacts with the substrate to produce a color reaction product that can be measured. The concentration of Galectin-3 present in the sample can be estimated by comparing the measured value with the Galectin-3 standard curve.

[0166] In some embodiments, the sandwich method uses immunochromatography. The principle of immunochromatography is to first fix a specific antibody to a certain zone of a nitrocellulose membrane. When one end of the dry nitrocellulose is immersed in a sample (urine or serum), the sample will move forward along the membrane due to capillary action. When it moves to the area where the antibody is fixed, the corresponding antigen in the sample will specifically bind to the antibody. If immunocolloidal gold or immunoenzyme staining is used, the area can show a certain color, thereby achieving specific immunodiagnosis. In some embodiments, in addition to colloidal gold, immunochromatography can also use colored microspheres, fluorescent microspheres, time-resolved fluorescent microspheres, quantum dot fluorescent microspheres, aggregation-induced luminescent microspheres, upconversion luminescent microspheres, magnetic microparticles, surface-enhanced Raman scattering materials, and other nanoparticles. The groups modified on the surface of the nanoparticles or the charges carried are connected to the detection antibodies through chemical bonds or physical adsorption to form antibody-nanoparticle complexes (chemical bond connection is mainly through carbodiimide functional group-mediated connection, and physical adsorption is mainly through charge adsorption). The antibody-nanoparticle complex is sprayed onto a glass fiber membrane or a polyester membrane and dried to prepare a release pad; the nitrocellulose membrane is coated with a T line (detection line) capture antibody and a C line (quality control line) protein; the glass cellulose membrane is soaked in a treatment solution (such as 5% trehalose + 0.5% PVP-K30 + 0.5% BSA + 0.5% Tween20 + 0.05M / L Tris-HCl) to prepare a sample pad; an absorption pad (cotton lint filter paper or plant fiber filter paper). After assembling in the order of absorption pad-NC membrane-release pad (some processes do not have)-sample pad through a support (PVC board), the strips are cut and the card is mounted for testing. The sample first contacts the antibody-nanoparticle complex in the presence of Galectin-3 to form a Galectin-3-antibody-nanoparticle complex. Under the chromatographic force, the complex passes through the NC membrane to reach the T line, and forms a capture antibody-Galectin-3-antibody-nanoparticle complex with the T line capture antibody and is fixed on the NC membrane. By using the instrument to interpret the signal of the nanoparticles, the content of Galectin-3 protein can be calculated. The content of Galectin-3 protein is directly proportional to the signal of the nanoparticles.

[0167] In some embodiments, the sandwich method uses a chemiluminescence immunoassay (CLIA), and in some exemplary kits, a magnetic separation reagent, a first reagent, a second reagent, and a Galecin-3 protein series calibrator are included. Magnetic separation reagent: The surface-modified groups or charges of magnetic bead nanoparticles are connected to antibodies through chemical bonds or physical adsorption to form antibody-nanoparticle complexes (chemical bond connection is mainly through carbodiimide functional group-mediated connection, and physical adsorption is mainly through charge adsorption); first reagent: antibodies labeled with biotin, horseradish peroxidase, alkaline phosphatase, terpyridine ruthenium, N-hydroxysuccinimide biotin ester, etc.; second reagent: horseradish peroxidase, alkaline phosphatase, terpyridine ruthenium, etc. labeled streptavidin. The sample reacts with the antibody-magnetic bead nanoparticle complex to form a Galectin-3-antibody-magnetic bead nanoparticle complex in the presence of Galectin-3. The first reagent is added to react to form a labeled antibody-Galectin-3-antibody AAA-magnetic bead nanoparticle complex. The second reagent is added, and then the corresponding luminescent substrate such as luminol, AMPPD, etc. is added. The luminescent signal is read to calculate the Galectin-3 protein content. The Galectin-3 protein content is proportional to the luminescent signal.

[0168] In some embodiments, the sandwich method uses a detection method based on a microfluidic chip. Galectin 3 antibody 1 is coated in the chip reaction chamber as a stationary phase, Galectin 3 antibody 2 is coated on fluorescent microspheres, and the immune microspheres are pre-drained and fixed in the microfluidic chip. When the sample is added to the microfluidic chip sample port, the sample flows into the microchannel through the air pump, and the Galectin 3 analyte in the sample reacts with the antibody coated on the fluorescent microspheres and the capture antibody on the chip in turn. This method is based on the microfluidic chip as a carrier, and the immune detection reaction is carried out in the microfluidic reactor inside the microfluidic chip. A single chip is used for single-person testing, and the prepared kit is used for testing. After manual sample addition, the instrument realizes the liquid flow control of the analyte in the microfluidic chip, the regulation of the immune reaction, and the cleaning steps after the reaction. The instrument collects the fluorescent signal and calculates the specific reaction value.

[0169] In some embodiments, the sandwich method uses a single molecule immune array detection (Simoa). This embodiment uses the principle of the double antibody sandwich method of the enzyme-linked immunosorbent assay and combines the Simoa (Single Molecular Array) single molecule immune array analysis technology, which can capture single molecules in microwells of femtoliter size, allowing digital reading of single magnetic bead signals, and converting digital signals into the concentration of molecules to be tested, greatly improving the sensitivity of detection. The embodiment comprises magnetic beads coated with capture antibodies, Galectin-3 detection antibodies coupled with a first marker, β-galactosidase coupled with a second marker, enzyme reaction luminescent substrates and Galectin-3 standards. The capture antibody in the magnetic beads coated with the capture antibody is used to specifically bind to the Galectin-3 antigen, the first marker in the Galectin-3 detection antibody coupled with the first marker is used to connect to the second marker in the β-galactosidase coupled with the second marker, and the Galectin-3 detection antibody is used to specifically bind to the Galectin-3 antigen. The first marker in the CCL1 detection antibody coupled with the first marker is biotin or a biotin derivative, and biotin includes biotin tetraethylene glycol-N-hydroxysuccinimide ester. The second marker of β-galactosidase coupled with the second marker is streptavidin. In some embodiments, the preparation method of magnetic beads coated with capture antibodies includes: liquid replacement treatment of the capture antibody with magnetic bead coupling buffer, and activation of the magnetic beads, and then coupling the replaced capture antibody with the activated magnetic beads. After the coupling product is washed with a cleaning solution, it is blocked with a blocking buffer, and then washed with a cleaning solution to obtain the capture antibody-coated magnetic beads. In some embodiments, the activation conditions in the activation magnetic bead step are: activation temperature 2-8°C, activation time 20-40min. In some embodiments, the activation reagent in the activation magnetic bead step includes EDC solution, and the concentration of EDC solution is 0.1-0.5mg / mL. In some embodiments, the coupling conditions in the coupling step are: coupling temperature 2-8°C, coupling time 1.5-2.5h. In some embodiments, the concentration of activated magnetic beads in the coupling step is 1.3×10 9 -1.5×10 9 / mL; the concentration of the captured antibody after displacement is 0.1-0.3 mg / mL. In some embodiments, the preparation method of the biotinylated detection antibody includes: subjecting the detection antibody to liquid displacement treatment with a biotinylation reaction buffer, and then connecting the replaced detection antibody to biotin, and the obtained product is purified to obtain the biotinylated detection antibody. The molar ratio of the detection antibody to biotin is 1:30-1:50. In some embodiments, the detection method also includes a streptavidin-β-galactosidase solution and a fluorescent substrate solution, and the fluorescent substrate includes resorufin-β-D-galactoside.

[0170] Method for determining Galectin-3 levels in human tissue samples

[0171] The present invention provides a method for determining the total protein level of Galectin-3 in a human tissue or cell sample. In some embodiments, the sample is normal human tissue or cell, diseased tissue or cell, tumor tissue or cell, diseased and adjacent tissue or cell of a tumor, cardiovascular disease, various cancers, rheumatoid, fibrotic organ tissue or cell, etc. The method is to detect the level and distribution of Galectin-3 in the sample using known detection methods in the fields of immunohistochemistry or Western Blot.

[0172] application

[0173] The present invention provides a method for determining the level of human Galectin-3 full-length protein and a method for determining the level of human Galectin-3 total protein, which can more accurately determine the content of Galectin-3 full-length protein or Galectin-3 total protein in a sample. By using the antibodies disclosed herein, and in combination with immunoassays known in the art, such as ELISA, immunochromatography, chemiluminescence, etc., the content of Galectin-3 full-length protein or Galectin-3 total protein in a sample (including human Galectin-3 full-length protein and Galectin-3 protein cleaved into fragments by protease) can be reliably and reproducibly detected. The method for determining the level of human Galectin-3 full-length protein provided by the present invention is used in combination with the method for determining the level of human Galectin-3 total protein, and can accurately determine the level of human Galectin-3 full-length protein in the analysis sample and the level of Galectin-3 protein fragments with CRD structure produced after enzymatic decomposition. The method of the present invention provides a powerful tool for studying and analyzing the relationship between the full-length Galectin-3 protein, the Galectin-3 protein fragments with CRD structure produced after enzymatic decomposition, and MMPs. The method of the present invention provides a powerful tool for studying the association between the full-length Galectin-3 protein, the Galectin-3 protein fragments with CRD structure produced after enzymatic decomposition and diseases such as heart failure, cancer, and inflammation. The method of the present invention provides a powerful tool for studying the biological function of Galectin-3 and its mechanism of action in related diseases.

[0174] The method for determining the level of Galectin-3 full-length protein or Galectin-3 total protein in a human body fluid sample provided by the present invention can be used to detect subjects at risk of developing HF or identify subjects suffering from HF. The method can monitor changes in Galectin-3 levels in patients or other subjects with identified risks of developing HF. Subjects at risk of developing HF can monitor their Galectin-3 levels over a period of time, such as once a week, once a month, once a quarter, twice a year, once a year, or once every two years. Galectin-3 levels can be used as a diagnostic marker to determine whether a subject has HF, the stage or severity, or by comparing the Galectin-3 level test result data in the subject's sample over a period of time, combined with data related to the severity or stage of the HF disease to predict his prognosis. The method described in the present invention can be combined with other methods commonly used in the art for diagnosis and / or prediction of prognosis (e.g., echocardiogram using Doppler analysis, radionuclide ventriculoscopy, magnetic resonance imaging (MRI), complete blood cell count, urinalysis, serum electrolytes, glycohemoglobin and lipids, tests of renal and liver function, tests of thyroid function, chest X-ray, 12-lead electrocardiogram, blood tests for biomarkers such as BNP, etc.).

[0175] The method for determining the level of Galectin-3 full-length protein or Galectin-3 total protein in human body fluid samples provided by the present invention can also be combined with other indicators to detect the occurrence, progression and prognosis of cardiovascular diseases such as coronary heart disease and atrial fibrillation.

[0176] The method for determining the level of Galectin-3 full-length protein or Galectin-3 total protein in human body fluid samples provided by the present invention can also be used for cancer monitoring. Galectin-3 participates in angiogenesis, increases the aggregation of tumor cells and their adhesion to vascular endothelial cells to promote tumor metastasis, and is closely related to the occurrence and development of tumors. It has a great correlation with the occurrence and development of various tumors, such as but not limited to lung cancer, thyroid cancer, breast cancer, ovarian cancer, endometrial cancer, pancreatic cancer, gastric cancer, esophageal cancer, colon cancer, etc. Many studies have shown that Galectin-3 can be used as an indicator for predicting the diagnosis and prognosis of cancer, especially thyroid cancer. Galectin-3 is not expressed in normal thyroid tissue, and is expressed in small amounts in benign thyroid tumors, but the expression rate of malignant thyroid cancer is higher, and Galectin-3 is positively correlated with the malignancy of thyroid cancer. Galectin-3 can be used as an indicator for uncertain cytological examination of thyroid cancer, and has been clinically verified and used in many countries and regions.

[0177] The method for determining the total protein level of Galectin-3 in human tissue or cell samples provided by the present invention can be used to locate, qualitatively and relatively quantitatively study the Galectin-3 levels in various human cells, normal tissues, diseased tissues, tumors, diseased and adjacent tissues of tumors, and the distribution thereof, and can also detect the content of Galectin-3 in the body and the intracellular and extracellular localization thereof. The method described in the present invention can be used for the diagnosis and qualitative identification of malignant tumors, the determination of the primary site of metastatic malignant tumors, the further pathological classification of certain types of tumors, the diagnosis of soft tissue tumors, and the selection of treatment plans for clinical practice.

[0178] Other uses: The method for determining the total protein level of Galectin-3 in a human body fluid sample or the method for determining the total protein level of Galectin-3 in a human tissue or cell sample provided by the present invention can also be used for the detection, diagnosis or mechanism research of diseases related to the function of Galectin-3 in promoting tissue fibroblasts and secretion of pro-inflammatory cytokines, such as rheumatoid arthritis, chronic kidney disease, bronchial asthma, chronic obstructive pulmonary disease, primary Sjögren's syndrome, ulcerative colitis, cirrhosis, fibrosis of organs such as kidneys, lungs, liver, sepsis and other diseases.

[0179] Reagent test kit

[0180] The present invention provides a human Galectin-3 full-length protein level determination kit, and the present invention also provides a human Galectin-3 total protein level determination kit. The kit can be used to predict the risk level of HF, diagnose HF, determine the severity of HF or predict the prognosis of HF patients. It can also be used to predict or diagnose thyroid cancer or other related cancers, and can also be used to predict or assist in the diagnosis of other diseases related to Galectin-3 levels. The kit can also be used for scientific research related to Galectin-3 levels. The kit includes one or more antibodies or antigen-binding fragments thereof for quantitatively detecting the level of Galectin-3 in a sample. The antibody or antigen-binding fragment thereof is specific to Galectin-3 protein fragments or Galectin-3 proteins. The capture binding portion that can be provided in the kit is pre-connected to a solid surface, such as but not limited to a plastic or glass container or a microsphere or a membrane. The kit can also include a container for mixing the sample with the binding portion. Such a container can be suitable for use in a detection instrument capable of detecting a signal generated by the detection binding portion. The kit can also include one or more reagents (e.g., different antibodies) for measuring the level of a second marker indicating the same disease.

[0181] The kit of the present invention may additionally include one or more of the following: (1) instructions for using the kit to determine the level of human Galectin-3 protein; (2) a solid phase (e.g., an ELISA plate or a reagent strip) on which any such antibody is immobilized; (3) a label or insert approved by a regulatory agency indicating diagnostic, prognostic or therapeutic use or any combination thereof.

[0182] Most of the current detection antibodies, detection methods or detection kits for Galectin-3 protein do not clearly state the range of Galectin-3 protein sites to be detected. Some detection methods or detection kits even use polyclonal antibodies, and it is impossible to determine whether the detection result is the Galectin-3 full-length protein content or the Galectin-3 total protein content. When using polyclonal antibodies, the detection result will be greater than the actual content of Galectin-3 protein in some detection methods. At present, except for the present invention, there are no other detection antibodies, detection methods or detection kits that exclude the influence of galactose, lactose, laminin, glycoprotein, ligand, etc. in the sample on the detection of Galectin-3 protein content. The detection results that do not exclude the influence of galactose, lactose, laminin, glycoprotein, ligand, etc. in the sample are controversial.

[0183] The present invention provides a method for determining the level of human Galectin-3 full-length protein and a method for determining the level of human Galectin-3 total protein, which can more accurately determine the content of Galectin-3 full-length protein or Galectin-3 total protein in a sample. By using the antibodies disclosed herein, and in combination with immunoassays known in the art, such as ELISA, immunochromatography, chemiluminescence, etc., the content of Galectin-3 full-length protein or Galectin-3 total protein in a sample (including human Galectin-3 full-length protein and Galectin-3 protein cleaved into fragments by protease) can be reliably and reproducibly detected. The method for determining the level of human Galectin-3 full-length protein provided by the present invention is used in combination with the method for determining the level of human Galectin-3 total protein, and can accurately determine the level of human Galectin-3 full-length protein in the analysis sample and the level of Galectin-3 protein fragments with CRD structure produced after enzymatic decomposition. The method of the present invention provides a powerful tool for studying and analyzing the relationship between the full-length Galectin-3 protein, the Galectin-3 protein fragments with CRD structure produced after enzymatic decomposition, and MMPs. The method of the present invention provides a powerful tool for studying the association between the full-length Galectin-3 protein, the Galectin-3 protein fragments with CRD structure produced after enzymatic decomposition and diseases such as heart failure, cancer, and inflammation. The method of the present invention provides a powerful tool for studying the biological function of Galectin-3 and its mechanism of action in related diseases.

[0184] The method for determining the level of Galectin-3 full-length protein or Galectin-3 total protein in a human body fluid sample provided by the present invention can be used to detect subjects at risk of developing HF or identify subjects suffering from HF. The method can monitor changes in Galectin-3 levels in patients or other subjects with identified risks of developing HF. Subjects at risk of developing HF can monitor their Galectin-3 levels over a period of time, such as once a week, once a month, once a quarter, twice a year, once a year, or once every two years. Galectin-3 levels can be used as a diagnostic marker to determine whether a subject has HF, the stage or severity, or by comparing the Galectin-3 level test result data in the subject's sample over a period of time, combined with data related to the severity or stage of the HF disease to predict his prognosis. The method described in the present invention can be combined with other methods commonly used in the art for diagnosis and / or prediction of prognosis (e.g., echocardiogram using Doppler analysis, radionuclide ventriculoscopy, magnetic resonance imaging (MRI), complete blood cell count, urinalysis, serum electrolytes, glycohemoglobin and lipids, tests of renal and liver function, tests of thyroid function, chest X-ray, 12-lead electrocardiogram, blood tests for biomarkers such as BNP, etc.).

[0185] The method for determining the level of Galectin-3 full-length protein or Galectin-3 total protein in human body fluid samples provided by the present invention can also be combined with other indicators to detect the occurrence, progression and prognosis of cardiovascular diseases such as coronary heart disease and atrial fibrillation.

[0186] The method for determining the level of Galectin-3 full-length protein or Galectin-3 total protein in human body fluid samples provided by the present invention can also be used for cancer monitoring. Galectin-3 participates in angiogenesis, increases the aggregation of tumor cells and their adhesion to vascular endothelial cells to promote tumor metastasis, and is closely related to the occurrence and development of tumors. It has a great correlation with the occurrence and development of various tumors, such as but not limited to lung cancer, thyroid cancer, breast cancer, ovarian cancer, endometrial cancer, pancreatic cancer, gastric cancer, esophageal cancer, colon cancer, etc. Many studies have shown that Galectin-3 can be used as an indicator for predicting the diagnosis and prognosis of cancer, especially thyroid cancer. Galectin-3 is not expressed in normal thyroid tissue, and is expressed in small amounts in benign thyroid tumors, but the expression rate of malignant thyroid cancer is higher, and Galectin-3 is positively correlated with the malignancy of thyroid cancer. Galectin-3 can be used as an indicator for uncertain cytological examination of thyroid cancer, and has been clinically verified and used in many countries and regions.

[0187] The method for determining the total protein level of Galectin-3 in human tissue or cell samples provided by the present invention can be used to locate, qualitatively and relatively quantitatively study the Galectin-3 levels in various human cells, normal tissues, diseased tissues, tumors, diseased and adjacent tissues of tumors, and the distribution thereof, and can also detect the content of Galectin-3 in the body and the intracellular and extracellular localization thereof. The method described in the present invention can be used for the diagnosis and qualitative identification of malignant tumors, the determination of the primary site of metastatic malignant tumors, the further pathological classification of certain types of tumors, the diagnosis of soft tissue tumors, and the selection of treatment plans for clinical practice.

[0188] Other uses: The method for determining the total protein level of Galectin-3 in a human body fluid sample or the method for determining the total protein level of Galectin-3 in a human tissue or cell sample provided by the present invention can also be used for the detection, diagnosis or mechanism research of diseases related to the function of Galectin-3 in promoting tissue fibroblasts and secretion of pro-inflammatory cytokines, such as rheumatoid arthritis, chronic kidney disease, bronchial asthma, chronic obstructive pulmonary disease, primary Sjögren's syndrome, ulcerative colitis, cirrhosis, fibrosis of organs such as kidneys, lungs, liver, sepsis and other diseases.

[0189] In a first aspect, the present application provides an antibody or an antigen-binding portion thereof, wherein the antibody is capable of binding to human Galectin-3, and the binding epitope is located in the N-terminal 1-62 amino acid sequence region of human Galectin-3 as shown in SEQ ID NO:1.

[0190] In some embodiments, the antibody comprises HCDR1 shown in SEQ ID NO:3, HCDR2 shown in SEQ ID NO:4, HCDR3 shown in SEQ ID NO:5, LCDR1 shown in SEQ ID NO:6, LCDR2 shown in SEQ ID NO:7 and LCDR3 shown in SEQ ID NO:8, the antibody heavy chain variable region sequence is shown in SEQ ID NO:27, and the light chain variable region sequence is shown in SEQ ID NO:28.

[0191] In some embodiments, the antibody comprises a heavy chain variable region sequence as shown in SEQ ID NO:27.

[0192] In some embodiments, the antibody comprises a light chain variable region sequence as shown in SEQ ID NO:28.

[0193] In some embodiments, the antibody comprises a heavy chain variable region sequence as shown in SEQ ID NO:27 and a light chain variable region sequence as shown in SEQ ID NO:28.

[0194] In some embodiments, the antibody comprises HCDR1 shown in SEQ ID NO:9, HCDR2 shown in SEQ ID NO:10, HCDR3 shown in SEQ ID NO:11, LCDR1 shown in SEQ ID NO:12, LCDR2 shown in SEQ ID NO:13 and LCDR3 shown in SEQ ID NO:14, the antibody heavy chain variable region sequence is shown in SEQ ID NO:29, and the light chain variable region sequence is shown in SEQ ID NO:30.

[0195] In some embodiments, the antibody comprises a heavy chain variable region sequence as shown in SEQ ID NO:29.

[0196] In some embodiments, the antibody comprises a light chain variable region sequence as shown in SEQ ID NO:30.

[0197] In some embodiments, the antibody comprises a heavy chain variable region sequence as shown in SEQ ID NO:29 and a light chain variable region sequence as shown in SEQ ID NO:30.

[0198] In a second aspect, the present application provides an antibody or an antigen-binding portion thereof, wherein the antibody is capable of binding to human Galectin-3, and the binding epitope is located in the N-terminal 63-250 amino acid sequence region of human Galectin-3 as shown in SEQ ID NO:2.

[0199] In some embodiments, the antibody comprises HCDR1 shown in SEQ ID NO:15, HCDR2 shown in SEQ ID NO:16, HCDR3 shown in SEQ ID NO:17, LCDR1 shown in SEQ ID NO:18, LCDR2 shown in SEQ ID NO:19 and LCDR3 shown in SEQ ID NO:20, the antibody heavy chain variable region sequence is shown in SEQ ID NO:31, and the light chain variable region sequence is shown in SEQ ID NO:32.

[0200] In some embodiments, the antibody comprises a heavy chain variable region sequence as shown in SEQ ID NO:31.

[0201] In some embodiments, the antibody comprises a light chain variable region sequence as shown in SEQ ID NO:32.

[0202] In some embodiments, the antibody comprises a heavy chain variable region sequence as shown in SEQ ID NO:31 and a light chain variable region sequence as shown in SEQ ID NO:32.

[0203] In some embodiments, the antibody comprises HCDR1 shown in SEQ ID NO:21, HCDR2 shown in SEQ ID NO:22, HCDR3 shown in SEQ ID NO:23, LCDR1 shown in SEQ ID NO:24, LCDR2 shown in SEQ ID NO:25 and LCDR3 shown in SEQ ID NO:26, the antibody heavy chain variable region sequence is shown in SEQ ID NO:33, and the light chain variable region sequence is shown in SEQ ID NO:34.

[0204] In some embodiments, the antibody comprises a heavy chain variable region sequence as shown in SEQ ID NO:33.

[0205] In some embodiments, the antibody comprises a light chain variable region sequence as shown in SEQ ID NO:34.

[0206] In some embodiments, the antibody comprises a heavy chain variable region sequence as shown in SEQ ID NO:33 and a light chain variable region sequence as shown in SEQ ID NO:34.

[0207] In some embodiments, SEQ ID NOs: 3 to 34 are derived from a mouse.

[0208] In a third aspect, the present application provides an antibody combination product comprising a first antibody and a second antibody, wherein the first antibody and the second antibody are selected from the antibodies or antigen-binding portions thereof described in the first and second aspects.

[0209] In some embodiments, the first antibody is selected from the antibody or antigen binding portion thereof described in the first aspect and the second antibody is selected from the antibody or antigen binding portion thereof described in the second aspect.

[0210] In some embodiments, the first antibody is selected from the antibody or antigen binding portion thereof of the second aspect and the second antibody is selected from the antibody or antigen binding portion thereof of the first aspect.

[0211] In some embodiments, the first antibody and the second antibody are both selected from the antibodies or antigen-binding portions thereof described in the first aspect.

[0212] In some embodiments, the first antibody and the second antibody are both selected from the antibodies or antigen-binding portions thereof described in the second aspect.

[0213] In some embodiments, the first antibody is labeled with a detectable label.

[0214] In some embodiments, the second antibody is labeled with a detectable marker.

[0215] In some embodiments, the detectable label is selected from the group consisting of an enzyme, a prosthetic group, a fluorescent material, a luminescent material, a latex particle, a gold particle, a bioluminescent material, and a radioactive material.

[0216] In a fourth aspect, the present application provides a kit for detecting the level of galectin-3 in a sample from a human subject, comprising the antibody or antigen-binding portion thereof according to the first aspect and / or the second aspect or the antibody combination product according to the third aspect.

[0217] In some embodiments, the level of Galectin-3 is the level of human Galectin-3 full-length protein or the level of human Galectin-3 total protein.

[0218] In some embodiments, the total human Galectin-3 protein level is the sum of the full-length human Galectin-3 protein and the N-terminal amino acid fragment of human Galectin-3 from position 63 to 250.

[0219] In some embodiments, the total human Galectin-3 protein level is the sum of the full-length human Galectin-3 protein and the N-terminal 1-62 amino acid fragment of human Galectin-3.

[0220] In some embodiments, the level of Galectin-3 is the level of human Galectin-3 full-length protein.

[0221] In some embodiments, the level of Galectin-3 is the level of total human Galectin-3 protein.

[0222] In some embodiments, the kit uses a double antibody sandwich method to detect the level of galectin-3; the double antibody sandwich method is selected from ELISA, colloidal gold, immunochromatography, surface enhanced Raman scattering immunochromatography, chemiluminescence, microfluidics, and single molecule immunoarray.

[0223] In some embodiments, the kit is an ELISA detection kit, a colloidal gold detection kit, an immunochromatography detection kit, a surface enhanced Raman scattering immunochromatography detection kit, a chemiluminescence detection kit, a microfluidics detection kit, or a single molecule immunoarray detection kit.

[0224] In a fifth aspect, the present application provides use of the antibody or antigen-binding portion thereof described in the first aspect and / or the second aspect or the antibody combination product described in the third aspect in the preparation of a kit for detecting the level of galectin-3 in a biological sample.

[0225] In a sixth aspect, the present application provides a use of the antibody or its antigen-binding portion described in the first aspect and / or the second aspect, or the antibody combination product described in the third aspect, in the preparation of a kit for diagnosing or assisting in the diagnosis of a disease, wherein the disease is selected from cardiovascular disease, tumor, rheumatic immune disease, kidney disease, respiratory system disease, digestive system disease or infectious disease.

[0226] In some embodiments, the cardiovascular disease is heart failure, coronary heart disease, or atrial fibrillation.

[0227] In some embodiments, the tumor is thyroid cancer, breast cancer, ovarian cancer, gastric cancer, esophageal cancer, non-small cell lung cancer, colon adenocarcinoma, or endometrial cancer.

[0228] In some embodiments, the rheumatic immune disease is rheumatoid arthritis.

[0229] In some embodiments, the kidney disease is chronic kidney disease.

[0230] In some embodiments, the respiratory disease is bronchial asthma, chronic obstructive pulmonary disease, or primary Sjögren's syndrome.

[0231] In some embodiments, the digestive disease is ulcerative colitis or cirrhosis of the liver.

[0232] In some embodiments, the infectious disease is sepsis.

[0233] In a seventh aspect, the present application provides a method for detecting the level of human Galectin-3, the method comprising:

[0234] Labeling the first antibody or the second antibody in the antibody combination product of the third aspect with a detectable marker;

[0235] The level of human Galectin-3 was detected using the double antibody sandwich method;

[0236] The double antibody sandwich method is selected from ELISA, colloidal gold, immunochromatography, surface enhanced Raman scattering immunochromatography, chemiluminescence, microfluidics, and single molecule immunoarray.

[0237] In some embodiments, the antibody or antigen-binding portion thereof of the first aspect is labeled with a detectable label.

[0238] In some embodiments, the antibody or antigen-binding portion thereof of the second aspect is labeled with a detectable label.

[0239] In some embodiments, the level of human Galectin-3 is the level of human Galectin-3 full-length protein or the level of human Galectin-3 total protein.

[0240] In some embodiments, the total human Galectin-3 protein level is the sum of the full-length human Galectin-3 protein and the N-terminal amino acid fragment of human Galectin-3 from position 63 to 250.

[0241] In some embodiments, the total human Galectin-3 protein level is the sum of the full-length human Galectin-3 protein and the N-terminal 1-62 amino acid fragment of human Galectin-3.

[0242] In some embodiments, the level of human Galectin-3 is the level of human Galectin-3 full-length protein.

[0243] In some embodiments, the level of human Galectin-3 is the level of total human Galectin-3 protein.

[0244] In some embodiments, the total human Galectin-3 protein level is the sum of the full-length human Galectin-3 protein and the Galectin-3 protein cleaved into fragments by protease.

[0245] In some embodiments, the double antibody sandwich method is used to measure the level of human Galectin-3 protein, and one of the epitope antibodies within the amino acid range of positions 1-62 of the N-terminal protein of human Galectin-3 and the epitope antibodies within the amino acid range of positions 63-250 of the human Galectin-3 protein is used as a capture antibody, and the other antibody is used as a detection antibody.

[0246] In some embodiments, in the double antibody sandwich method, different epitope antibodies within the range of amino acids 1-62 at the N-terminus of human Galectin-3 protein are used as capture antibodies or detection antibodies.

[0247] In some embodiments, in the double antibody sandwich method, antibodies with different epitopes within the amino acid range of position 63-250 of human Galectin-3 protein are used as capture antibodies or detection antibodies.

[0248] In some embodiments, the level of human Galectin-3 protein is measured using immunohistochemistry, immunoblotting or immunoturbidimetry, which utilizes an antibody against an epitope within the amino acid range of positions 1-62 of the N-terminal protein of human Galectin-3 or an antibody against an epitope within the amino acid range of positions 63-250 of the human Galectin-3 protein.

[0249] In some embodiments, the antibody or antigen-binding portion thereof described in the first aspect or the second aspect binds to human Galectin-3 protein, and its binding is not affected by whether galactose, lactose, laminin, other glycoproteins or ligands bind to human Galectin-3 protein.

[0250] In some embodiments, the double antibody sandwich method includes but is not limited to ELISA, colloidal gold, immunochromatography, surface enhanced Raman scattering immunochromatography, chemiluminescence, microfluidics or single molecule immunoarray.

[0251] In some embodiments, the level of total human Galectin-3 protein can be detected using a sandwich method, a direct method, or an indirect method.

[0252] In an eighth aspect, the present application provides a method for diagnosing or assisting in the diagnosis of a disease, the method comprising:

[0253] Labeling the first antibody or the second antibody in the antibody combination product of claim 5 with a detectable marker;

[0254] Detecting the level of human Galectin-3 using a double antibody sandwich method, wherein the level of human Galectin-3 is the level of human Galectin-3 full-length protein or the level of human Galectin-3 total protein;

[0255] The double antibody sandwich method is selected from ELISA, colloidal gold, immunochromatography, surface enhanced Raman scattering immunochromatography, chemiluminescence, microfluidics, and single molecule immunoarray;

[0256] The disease is selected from cardiovascular disease, tumor, rheumatic immune disease, kidney disease, respiratory system disease, digestive system disease or infectious disease.

[0257] In some embodiments, the cardiovascular disease is heart failure, coronary heart disease, or atrial fibrillation.

[0258] In some embodiments, the tumor is thyroid cancer, breast cancer, ovarian cancer, gastric cancer, esophageal cancer, non-small cell lung cancer, colon adenocarcinoma, or endometrial cancer.

[0259] In some embodiments, the rheumatic immune disease is rheumatoid arthritis.

[0260] In some embodiments, the kidney disease is chronic kidney disease.

[0261] In some embodiments, the respiratory disease is bronchial asthma, chronic obstructive pulmonary disease, or primary Sjögren's syndrome.

[0262] In some embodiments, the digestive system disease is ulcerative colitis or cirrhosis of the liver.

[0263] In some embodiments, the infectious disease is sepsis.

[0264] In some embodiments, the level of human Galectin-3 is the level of human Galectin-3 full-length protein or the level of human Galectin-3 total protein.

[0265] In some embodiments, the total human Galectin-3 protein level is the sum of the full-length human Galectin-3 protein and the N-terminal amino acid fragment of human Galectin-3 from position 63 to 250.

[0266] In some embodiments, the total human Galectin-3 protein level is the sum of the full-length human Galectin-3 protein and the N-terminal 1-62 amino acid fragment of human Galectin-3.

[0267] In some embodiments, the level of human Galectin-3 is the level of human Galectin-3 full-length protein.

[0268] In some embodiments, the level of human Galectin-3 is the level of total human Galectin-3 protein.

[0269] In some embodiments, the total human Galectin-3 protein level is the sum of the full-length human Galectin-3 protein and the Galectin-3 protein cleaved into fragments by protease.

[0270] Example

[0271] The following only discloses one or several embodiments of the present invention, which cannot be used to limit the scope of the present invention. A person skilled in the art can understand that all or part of the processes of the above embodiments and equivalent changes made according to the claims of the present invention still fall within the scope of the invention.

[0272] Example 1 Monoclonal Antibody Preparation

[0273] The present invention provides a method for preparing Galectin-3 monoclonal antibody, comprising the following steps:

[0274] 1. After multiple immunizations of Balb / c mice with the recombinant Galectin-3 full-length protein, spleen cells and lymph nodes were taken and fused with Sp2 / 0 myeloma cells, and a monoclonal cell line was obtained after multiple rounds of screening; monoclonal antibody ascites was prepared and purified, and finally Galectin-3 monoclonal antibody was obtained. The specific steps are:

[0275] Female Balb / c mice aged 6-8 weeks were selected for immunization. For the first immunization, each mouse was injected with a recombinant Galectin-3 full-length protein emulsified with Freund's complete adjuvant at multiple points subcutaneously at a dose of 100 μg / mouse. After that, the recombinant Galectin-3 full-length protein emulsified with incomplete adjuvant was injected at a dose of 50 μg / mouse every 14 days for booster immunization. The booster immunization was repeated twice. 14 days after the third immunization, each mouse was injected with 50 μg of recombinant Galectin-3 full-length protein intraperitoneally for booster immunization. Immunization, 3 days later, blood was collected from the eye sockets, mice were killed, spleen and lymph nodes were taken to prepare cell suspension, cells were counted, Sp2 / 0 mouse myeloma cells with good growth status were taken according to 1 / 10-1 / 2 of the number of spleen cells, the two cells were mixed and centrifuged at 1200rpm for 10 minutes, polyethylene glycol PEG-1450 was added to fuse the two, and an equal volume of feeder cells was added, mixed and divided into 96-well cell plates (200μL / well), and cultured at 37°C, 5% carbon dioxide incubator. After 7 days, the supernatant of hybridoma cells in the 96-well cell culture plate was tested by indirect enzyme-linked immunosorbent assay.

[0276] Positive hybridoma cells with high OD values ​​were cloned and subcloned using the limiting dilution method. The limited dilution cells were cultured in a 96-well plate. When the clones grew to the 7th day, they were observed under a microscope. The supernatant of the wells with monoclones was selected for ELISA detection. The monoclone with the highest OD value was again limitedly diluted and inoculated into a 96-well plate. Subcloning was performed again according to the above method. This process was repeated until the positive well ratio was 100%, and a monoclonal cell line was obtained. After 3-5 subclones, the selected monoclonal cell line was expanded and cultured at 2×10 6 Cryopreservation of cells / tube; preparation of monoclonal antibody ascites.

[0277] After screening, monoclonal cell lines with epitopes within the 1st to 62nd amino acid range of the N-terminal protein of Galectin-3 were obtained, such as E15F10 and Q1E2.

[0278] Monoclonal cell lines with epitopes within the amino acid range of human Galectin-3 at position 63-250, such as Y7E12 and UV4E4.

[0279] 2. The specific steps of preparing monoclonal antibody ascites and purifying to finally obtain Galectin-3 monoclonal antibody are:

[0280] Healthy Balb / c mice aged 6-8 weeks were selected and injected intraperitoneally with Freund's incomplete adjuvant at a dose of 500 μL / mouse. Seven days later, monoclonal cells (about 1.0×10 6Each monoclonal cell was injected into 3 healthy Balb / c mice; 7-12 days later, the ascites was collected; centrifuged at 10000rpm for 10 minutes, the precipitate and the upper layer of fat were discarded, and the supernatant was collected. The ammonium sulfate precipitation method was used for crude purification, and then further purified using agarose affinity medium Protein A / G chromatography column to obtain highly pure Galectin-3 monoclonal antibodies.

[0281] 3. The effect of laminin on the binding of Galectin-3 monoclonal antibody to Galectin-3 protein, the specific steps are:

[0282] Laminin was diluted to a final concentration of 5 μg / mL with PBS coating solution, and 50 μL / well was added to the ELISA plate. After coating at 4°C for 12 hours, it was washed once with washing solution and patted dry. Blocking solution (PBS containing 1% BSA) was added at 200 μL / well, blocked at 37°C for 2 hours, and the plate was washed once. A series of different concentrations of Galectin-3 monoclonal antibodies to be tested were added at 50 μL / well, and Galectin-3 with a concentration of 1 μg / mL was added. Add 50 μL / well of n-3 full-length antigen, incubate at 37°C for 1 hour, wash the plate 3 times and pat dry; add HRP (horseradish peroxidase)-labeled goat anti-mouse IgG, 100 μL / well, incubate at 37°C for 30 minutes, wash the plate 3 times with a plate washer and pat dry; add 100 μL / well of TMB colorimetric solution to each well, after 10 minutes of color development, add 2M H2SO4 to terminate the reaction, 50 μL / well; finally, read the OD value at a wavelength of 450 nm using an enzyme reader.

[0283] Galectin-3 monoclonal antibody is affected by laminin Figure 2 shown.

[0284] Although the amino acids 1-62 are far from the CRD region, some antibodies with antigen binding epitopes within the amino acid range of 1-62 will be affected to varying degrees by laminin binding to Galectin-3 protein. Monoclonal antibodies with epitopes within the amino acid range of 1-62 of the N-terminal protein of Galectin-3 that are not affected by laminin binding to Galectin-3 protein were screened, such as E15F10 and Q1E2. The antigen binding epitope of the Q1E2 antibody is within the amino acid range of 12-33, and the antigen binding epitope of the E15F10 antibody is within the amino acid range of 36-62.

[0285] Monoclonal antibodies targeting the epitope of human Galectin-3 at amino acids 63-250 that are not affected by laminin binding to Galectin-3 protein, such as Y7E12 and UV4E4. The antigen binding epitopes of these antibodies are concentrated in the amino acid range of 63-113. Most antibodies with antigen binding epitopes in the amino acid range of 114-250 are affected by lactose or laminin.

[0286] 4. Monoclonal antibody gene sequence cloning and determination:

[0287] The SBA Clonotyping System-HRP kit from Southern Biothech was used to identify the subtypes of the heavy and light chains of the monoclonal antibodies according to the instructions. After identification, the heavy chains of the four antibodies were all IgG1, and the light chains were Kappa. According to the antibody subtype results, the antibody gene sequence was cloned using a mature technical route. Hybridoma cells with good growth status were collected, and the total RNA of the hybridoma cells was extracted using Trizol from Thermo Company. The mRNA was reverse transcribed into cDNA according to the instructions of PrimeScript II Reverse Transcriptase from Takara Company.

[0288] The specific operation process of reverse transcription is as follows:

[0289] Prepare a 10 μL total volume of template RNA / primer DNA premix, including 1 μL 10 μM concentration of specific primers, the sequence is: ATGGGTGCCAGTGTCTCTTAGGA (SEQ ID NO: 35), GAAGCCTCCAAGACCTTAGAAGGGAA (SEQ ID NO: 36), 4 μL 2.5 mM dNTP mixture, 5 μL RNA (total amount less than 5 μg). After mixing, treat at 65°C for 5 minutes and immediately put on ice.

[0290] Add 4 μL 5× PrimeScript II buffer, 20 units of RNase inhibitor, and 1 μL PrimeScript II RTase (200 units) to the premix, mix well, react at 42°C for 60 minutes, then at 70°C for 15 minutes, and cool on ice for later use.

[0291] Using cDNA as template for gene amplification, design Lambda chain, Kappa chain, heavy chain downstream primers and upstream universal primers:

[0292] F:AAGCAGTGGTATCAACGCAGA(SEQ ID NO:37)

[0293] Rκ:AACATTGATGTCTTTGGGGTAGAA (SEQ ID NO:38)

[0294] Rλ:AATCGTACACACCAGTGTGTGGG (SEQ ID NO:39)

[0295] RH:AGGGATCCAGAGTTCCAGGT(SEQ ID NO:40)

[0296] PCR was performed using the first strand of cDNA as a template, with a reaction system of 50 μL.

[0297] PCR reaction system: template 3μl, dNTPs 1μL, upstream and downstream primers (10μM) 2.5μL each, 5×PCR buffer 10μL, ddH2O 30.5μL, Taq enzyme (5μ / μL) 0.5μL.

[0298] The product was purified and recovered by agarose gel electrophoresis, and inserted into the pMD-18T vector after A addition reaction with rTaq DNA polymerase, and transformed into DH5α competent cells. After the colonies grew, 4 clones of heavy chain and light chain gene clones were taken for sequencing.

[0299] The E15F10 monoclonal antibody or its antigen-binding portion comprises:

[0300] The heavy chain variable region HCDR1 as set forth in SEQ ID NO. 3;

[0301] The heavy chain variable region HCDR2 as set forth in SEQ ID NO.4;

[0302] The heavy chain variable region HCDR3 as set forth in SEQ ID NO.5;

[0303] The light chain variable region LCDR1 as set forth in SEQ ID NO.6;

[0304] The light chain variable region LCDR2 as set forth in SEQ ID NO.7;

[0305] The light chain variable region LCDR3 as set forth in SEQ ID NO.8;

[0306] The heavy chain variable region sequence of the E15F10 monoclonal antibody is shown in SEQ ID NO:27, and the light chain variable region sequence is shown in SEQ ID NO:28.

[0307] The Q1E2 monoclonal antibody or its antigen-binding portion comprises:

[0308] The heavy chain variable region HCDR1 as set forth in SEQ ID NO.9;

[0309] The heavy chain variable region HCDR2 as set forth in SEQ ID NO.10;

[0310] The heavy chain variable region HCDR3 as set forth in SEQ ID NO.11;

[0311] The light chain variable region LCDR1 as set forth in SEQ ID NO. 12;

[0312] The light chain variable region LCDR2 as set forth in SEQ ID NO. 13;

[0313] The light chain variable region LCDR3 as set forth in SEQ ID NO. 14;

[0314] The heavy chain variable region sequence of the Q1E2 monoclonal antibody is shown in SEQ ID NO:29, and the light chain variable region sequence is shown in SEQ ID NO:30.

[0315] The UV4E4 monoclonal antibody or antigen-binding portion thereof comprises:

[0316] The heavy chain variable region HCDR1 as set forth in SEQ ID NO.15;

[0317] The heavy chain variable region HCDR2 as set forth in SEQ ID NO.16;

[0318] The heavy chain variable region HCDR3 as set forth in SEQ ID NO.17;

[0319] The light chain variable region LCDR1 as set forth in SEQ ID NO. 18;

[0320] The light chain variable region LCDR2 as set forth in SEQ ID NO. 19;

[0321] The light chain variable region LCDR3 as set forth in SEQ ID NO. 20;

[0322] The heavy chain variable region sequence of the UV4E4 monoclonal antibody is shown in SEQ ID NO:31, and the light chain variable region sequence is shown in SEQ ID NO:32.

[0323] The Y7E12 monoclonal antibody or antigen-binding portion thereof comprises:

[0324] The heavy chain variable region HCDR1 as set forth in SEQ ID NO.21;

[0325] The heavy chain variable region HCDR2 as set forth in SEQ ID NO.22;

[0326] The heavy chain variable region HCDR3 as set forth in SEQ ID NO.23;

[0327] The light chain variable region LCDR1 as set forth in SEQ ID NO.24;

[0328] The light chain variable region LCDR2 as set forth in SEQ ID NO.25;

[0329] The light chain variable region LCDR3 as set forth in SEQ ID NO.26;

[0330] The heavy chain variable region sequence of the Y7E12 monoclonal antibody is shown in SEQ ID NO:33, and the light chain variable region sequence is shown in SEQ ID NO:34.

[0331] Example 2 Application of Antibodies in Galectin-3 Protein Sandwich ELISA Detection Kit

[0332] The present invention provides an ELISA detection kit for detecting the full-length Galectin-3 protein in human fluid samples, and the kit adopts a double antibody sandwich detection method. The present invention provides an ELISA detection kit for detecting the full-length Galectin-3 protein in human fluid samples. There are two ways to combine the Galectin-3 protein capture antibody and the Galectin-3 protein detection antibody: (1) an epitope antibody within the amino acid range of positions 1-62 of the N-terminal protein of Galectin-3 is used as a capture antibody, and an epitope antibody within the amino acid range of positions 63-250 of the Galectin-3 protein is used as a detection antibody; (2) an epitope antibody within the amino acid range of positions 63-250 of the Galectin-3 protein is used as a capture antibody, and an epitope antibody within the amino acid range of positions 1-62 of the N-terminal protein of Galectin-3 is used as a detection antibody. Any one of the two methods can be selected as the best method, such as the capture antibody is UV4E4 and the detection antibody is E15F10.

[0333] The present invention also provides an ELISA detection kit for detecting Galectin-3 total protein in human fluid samples, and the kit adopts a double antibody sandwich detection method. The present invention is an ELISA detection kit for detecting Galectin-3 total protein in human fluid samples. The Galectin-3 protein capture antibody and the Galecitn-3 protein detection antibody are respectively antibodies with different epitopes within the range of amino acids 1-62 at the N-terminus of the Galectin-3 protein, and the best combination is selected after pairing, such as the capture antibody is Q1E2 and the detection antibody is E15F10. Or the Galectin-3 protein capture antibody and the Galecitn-3 protein detection antibody are respectively antibodies with different epitopes within the range of amino acids 63-250 of the Galectin-3 protein, and the best combination is selected after pairing, such as the capture antibody is UV4E4 and the detection antibody is Y7E12.

[0334] The ELISA detection kit for the full-length Galectin-3 protein and the ELISA detection kit for the total Galectin-3 protein in this embodiment are basically the same except that the combination of the capture antibody and the labeled antibody is different. The specific implementation steps are as follows:

[0335] The ELISA detection kit for detecting Galectin-3 protein in human body fluid samples includes: Galectin-3 standard, human serum Galectin-3 positive control, Galectin-3 protein capture antibody coated reaction strip plate, Galectin-3 protein detection antibody, biological sample diluent, washing solution, and color development solution.

[0336] 1. The following is the preparation of each reagent:

[0337] (1) Galectin-3 standard: Galectin-3 protein was dissolved in 0.01 mol / L PBS solution, pH 7.4, 0.1% BSA, and the final concentration of Galectin-3 was 1000 μg / mL. When used, it was diluted with the standard solution to seven gradients of 60 ng / mL, 40 ng / mL, 20 ng / mL, 10 ng / mL, 5 ng / mL, 1 ng / mL and 0.1 ng / mL.

[0338] (2) Galectin-3 positive control sample: human serum with known concentration.

[0339] (3) Biological sample diluent: serum diluent, immunochemistry technology product number 649.

[0340] (4) Standard diluent: In the detection of human serum and plasma samples, 20% FBS diluted in PBS was used; in the detection of cell culture medium supernatant samples, cell culture medium was used; in the detection of cell lysate samples, cell lysate was used.

[0341] (5) Antibody diluent: Dissolve BSA in PBS solution to prepare a BSA concentration of 1%.

[0342] (6) Washing solution: PBST

[0343] (7) Galectin-3 antibody mixture: Galectin-3 detection antibody is labeled with HRP and diluted at a working concentration of 1:1000. It is prepared with antibody diluent before use and used immediately.

[0344] (8) Color developing solution: TMB color developing solution.

[0345] (9) ELISA plate: This is a white ELISA plate pre-embedded with Galectin-3 capture antibody and sealed. It is air-dried on a clean bench and then vacuum-sealed. When used, it is removed from the sealed bag and the remaining ELISA strips are returned to the sealed bag and stored at 4°C.

[0346] The Galectin-3 capture antibody coating solution was diluted to 4μg / mL. The antibody coating solution is 0.05M NaHCO3 / Na2CO3 buffer, pH=9.6, and the specific preparation method is: 1.46g NaHCO3 and 0.75g Na2CO3 are dissolved in 500mL ddH2O. After diluting the antibody, add 60μL of antibody to each well of the ELISA plate to ensure that the antibody covers the entire bottom of the well. Seal with a sealing film, place in a 4℃ refrigerator, and coat for 14-16h. Take out the ELISA plate, spin dry the remaining antibody coating solution and pat dry on absorbent paper. Wash three times with detergent, 3min each time. Block overnight with 200μL 10% FBS diluted in PBS. After washing 3 times with detergent, remove the detergent and air dry.

[0347] 2. The method for detecting the content of Galectin-3 protein in biological samples using the composition of the ELISA kit and the matching microplate reader is as follows:

[0348] (1) After pre-equilibration of the serum sample, standard sample, and positive control sample at room temperature, dilute the serum sample by half with biological sample diluent (if a sample with a very high concentration is encountered, a quarter or eighth dilution can be performed); dilute the standard sample to seven gradients of 60 ng / mL, 40 ng / mL, 20 ng / mL, 10 ng / mL, 5 ng / mL, 1 ng / mL, and 0.1 ng / mL, and directly use the standard sample diluent as the negative control;

[0349] (2) Add 100 μL of biological sample diluent to the ELISA plate, and add the above samples to the microwells of the ELISA plate in turn. Repeat the experiment twice for each sample, with 50 μL in each well. Incubate at 37°C for 3 hours. Galectin-3 will bind to the capture antibody on the surface of the solid phase carrier, that is, the antibody pre-coated in the well.

[0350] (3) Prepare the detection antibody complex with antibody diluent. The dilution ratio of HRP-labeled Galectin-3 detection antibody is 1:1000. Remove the sample from the microplate and pat dry on absorbent paper. Wash the microplate three times with PBST and add the freshly prepared antibody complex to the ELISA plate, 80 μL per well. Incubate the second time at 37°C for 0.5 h. The Galectin-3 detection antibody can bind to the Galectin-3 protein bound by the capture antibody in the first incubation.

[0351] (4) Wash three times with PSBT to remove unbound enzyme-labeled secondary antibody, add colorimetric solution for 10 min, and read the OD450 value on a microplate reader.

[0352] (5) The OD value is positively correlated with the Galectin-3 content in the sample. A standard curve is created with the standard concentration as the X-axis and the OD value as the Y-axis. Figure 3 or Figure 4 or Figure 5 (Galectin-3 protein cleaved by MMP2 was added as a control).

[0353] (6) Calculation of Galectin-3 concentration in the sample: If the coefficient of variation between the measured value of the positive control sample and the labeled value is less than 10%, it means that the measurement process is reliable. The concentration of human Galectin-3 protein in the measured sample can be calculated based on the standard curve obtained in the previous step.

[0354] Example 3 Application of Antibodies in Galectin-3 Protein Colloidal Gold Detection Kit

[0355] The present invention provides a colloidal gold detection kit for detecting the full-length Galectin-3 protein in human fluid samples, and the kit adopts a double antibody sandwich detection method. The present invention provides a colloidal gold detection kit for detecting the full-length Galectin-3 protein in human fluid samples. There are two ways to combine the Galectin-3 protein capture antibody and the Galectin-3 protein detection antibody: (1) an epitope antibody within the amino acid range of positions 1-62 of the N-terminal protein of Galectin-3 is used as a capture antibody, and an epitope antibody within the amino acid range of positions 63-250 of the Galectin-3 protein is used as a detection antibody; (2) an epitope antibody within the amino acid range of positions 63-250 of the Galectin-3 protein is used as a capture antibody, and an epitope antibody within the amino acid range of positions 1-62 of the N-terminal protein of Galectin-3 is used as a detection antibody. Any of the two methods can be selected as the best method, for example, the capture antibody is UV4E4 and the detection antibody is E15F10.

[0356] The present invention also provides a colloidal gold detection kit for detecting Galectin-3 total protein in human fluid samples, and the kit adopts a double antibody sandwich detection method. The present invention is a colloidal gold detection kit for detecting Galectin-3 total protein in human fluid samples. The Galectin-3 protein capture antibody and the Galecitn-3 protein detection antibody are respectively antibodies with different epitopes within the range of amino acids 1-62 at the N-terminus of the Galectin-3 protein, and the best combination is selected after pairing, such as the capture antibody is Q1E2 and the detection antibody is E15F10. Or the Galectin-3 protein capture antibody and the Galecitn-3 protein detection antibody are respectively antibodies with different epitopes within the range of amino acids 63-250 of the Galectin-3 protein, and the best combination is selected after pairing, such as the capture antibody is UV4E4 and the detection antibody is Y7E12.

[0357] The colloidal gold detection kit for the Galectin-3 full-length protein and the colloidal gold detection kit for the Galectin-3 total protein in this embodiment are basically the same except that the combination of the capture antibody and the labeling antibody is different. The specific implementation steps are as follows:

[0358] 1. Preparation of gold-labeled antibodies:

[0359] (1) Colloidal gold labeling process (the following steps are performed according to the amount used to prepare 100 mL of gold-labeled antibody).

[0360] (2) Measure 100 mL of colloidal gold solution into a beaker, add a rotor and place it on a magnetic stirrer, set the stirring speed to 200 rpm, and add 0.2 M K2CO3 solution until the solution pH is 8.2±0.05.

[0361] (3) Maintaining stirring at 200 rpm, add 1 mg of Galectin-3 detection antibody and place on a shaker (set speed to 80 rpm) for 30 min.

[0362] (4) Maintaining stirring at 200 rpm, add 1 mL of 10% BSA solution and block for 10 min.

[0363] (5) Stop stirring, transfer the solution to a centrifuge tube, centrifuge at 15000 rpm, 4°C for 10 min, discard the supernatant, add 100 mL of labeled cleaning solution, mix well, centrifuge at 15000 rpm, 4°C for 10 min. After centrifugation, remove the supernatant, resuspend the precipitate with 6 mL of gold-labeled resuspension solution (0.05 M / L Tris-HCl + 20% W / V trehalose + 0.5% W / V BSA + 0.5% W / V S9 + 0.5% W / V PVP-k30). Store at 2-8°C for later use.

[0364] 2. Preparation of labeling pad:

[0365] (1) Cutting of glass fiber: Cut the glass fiber film (30 cm*25 cm) into 0.9 cm cutting widths.

[0366] (2) After cutting the label pad and gold-labeled antibody, set the gold spraying instrument to spray at a rate of 4 μL / cm and perform the gold spraying operation. Then, place the label pad in a drying oven (37±1°C, humidity 10%-30%) and dry for 23-24 hours.

[0367] 3. Preparation of coating antibody:

[0368] (1) Prepare the NC membrane and PVC base plate for later use.

[0369] (2) Detection line coating: Add 1 mg / mL of capture antibody to the coating diluent (0.01 M / L PBS + 3% W / V trehalose).

[0370] (3) Quality control line: add 0.5 mg / mL of goat anti-mouse to the coating diluent.

[0371] (4) Clean the instrument, add the prepared test line and quality control line solutions to pumps 1 and 2, set the streaking solution volume to 1 μL / cm, and perform streaking. Place the NC membrane in a drying oven (temperature 50±1°C, humidity 10%-30%) and dry for 71-73 hours.

[0372] 4. Sample pad preparation:

[0373] A glass cellulose membrane (30 cm*25 cm) was cut to a width of 21 mm, and the instrument was set to spray at a rate of 4 μL / cm, a length of 300 mm, and an interval of 6 mm, and repeated 3 times. The sample pad treatment solution (0.05 M / L Tris-HCl + 3% W / V trehalose + 0.5% W / V BSA + 0.5% W / V S9 + 0.5% W / V PVP-k30) was used for gold spraying. Then, the label pad was placed in a drying oven (37 ± 1°C, humidity 10%-30%) and dried for 23-24 hours.

[0374] 5. Preparation of test strips:

[0375] Test strip preparation process (dry environment, temperature: 18-28°C, humidity 10%-30%)

[0376] (1) Place the dried marking pad, PVC base plate with NC film, absorbent paper, and sample pad on a Figure 6 Assemble as shown.

[0377] (2) Set the cutting width to 3.3 mm, and place the assembled gold label large board on the cutting machine for cutting. After the cutting is completed, collect the cut test strips into a test strip sealing box (humidity <30%) for storage.

[0378] (3) The test strips are packaged in a shell, with one test card and one bag of desiccant in each bag to seal the test cards.

[0379] 6. Test samples:

[0380] The method for measuring the content of Galectin-3 full-length protein or Galectin-3 total protein in biological samples using the composition of the colloidal gold kit and the supporting instrument is specifically as follows:

[0381] (1) After pre-equilibration of the serum sample, standard sample, and positive control sample at room temperature, dilute the serum sample by half with biological sample diluent (if a sample with very high concentration is encountered, a quarter and an eighth dilution can be performed); dilute the standard sample to eight gradients of 100 ng / mL, 50 ng / mL, 25 ng / mL, 10 ng / mL, 5 ng / mL, 2.5 ng / mL, 1 ng / mL, and 0.5 ng / mL; directly use the standard sample diluent as the negative control;

[0382] (2) Take out the reagent card that has been dried and sealed and place it on a horizontal table. Use a pipette to add 70 μL of the calibrator and sample to the sample well. After reacting for 15 minutes, insert it into the colloidal gold immunoassay analyzer for testing to obtain the corresponding T / C value.

[0383] (3) The T / C value is positively correlated with the Galectin-3 content in the sample. A standard curve is prepared with the standard concentration as the X-axis and the T / C value as the Y-axis. Figure 7 or Figure 8 or Fig. 9 (Galectin-3 protein cleaved by MMP2 was added as a control).

[0384] (4) Calculation of Galectin-3 concentration in the sample: If the coefficient of variation of the measured value of the positive control sample is less than 10% compared with the labeled value, it means that the measurement process is reliable. The concentration of human Galectin-3 in the measured sample can be calculated based on the standard curve obtained in the previous step.

[0385] Example 4 Application of Antibodies in Galectin-3 Protein Immunochromatographic Detection Kit

[0386] The present invention provides a protein fluorescence / quantum dot polystyrene microsphere detection kit for detecting the full-length Galectin-3 protein in human fluid samples, and the kit adopts a double antibody sandwich detection method. The present invention provides a protein fluorescence / quantum dot polystyrene microsphere detection kit for detecting the full-length Galectin-3 protein in human fluid samples. There are two ways to combine the Galectin-3 protein capture antibody and the Galectin-3 protein detection antibody: (1) an epitope antibody within the amino acid range of positions 1-62 of the N-terminal protein of Galectin-3 is used as a capture antibody, and an epitope antibody within the amino acid range of positions 63-250 of the Galectin-3 protein is used as a detection antibody; (2) an epitope antibody within the amino acid range of positions 63-250 of the Galectin-3 protein is used as a capture antibody, and an epitope antibody within the amino acid range of positions 1-62 of the N-terminal protein of Galectin-3 is used as a detection antibody. The two methods can be selected, and any one of the best methods is, for example, the capture antibody is UV4E4, and the detection antibody is E15F10.

[0387] The present invention also provides a protein fluorescence / quantum dot and other polystyrene microsphere detection kit for detecting Galectin-3 total protein in human fluid samples, and the kit adopts a double antibody sandwich detection method. The present invention is a protein fluorescence / quantum dot and other polystyrene microsphere detection kit for detecting Galectin-3 total protein in human fluid samples. The Galectin-3 protein capture antibody and the Galecitn-3 protein detection antibody are respectively antibodies with different epitopes within the range of amino acids 1-62 at the N-terminus of the Galectin-3 protein, and the best combination is selected after pairing, such as the capture antibody is Q1E2 and the detection antibody is E15F10. Or the Galectin-3 protein capture antibody and the Galecitn-3 protein detection antibody are respectively antibodies with different epitopes within the range of amino acids 63-250 of the Galectin-3 protein, and the best combination is selected after pairing, such as the capture antibody is UV4E4 and the detection antibody is Y7E12.

[0388] In this embodiment, the protein fluorescence / quantum dot polystyrene microsphere detection kit for the full-length Galectin-3 protein and the protein fluorescence / quantum dot polystyrene microsphere detection kit for the total Galectin-3 protein are basically the same except that the combination of the capture antibody and the labeled antibody is different. The specific implementation steps are as follows:

[0389] 1. Preparation of Antibody-Microsphere Conjugates

[0390] (1) Raw materials / consumables:

[0391] 1) Fluorescent microspheres, time-resolved fluorescent microspheres, quantum dot microspheres, aggregation-induced emission (AIE) fluorescent microspheres, colored microspheres

[0392] 2) Antibodies and antigens (warm up to room temperature before use).

[0393] 3) Activators EDC and Sulfo-NHS (EDC is packaged in small tubes in a dry environment, the lid is opened for a short time, sealed with sealing film after weighing, and stored at -20°C; Sulfo-NHS is stored at 4°C; return to room temperature before use).

[0394] 4) Activation solution Buffer A (0.05M / L MES pH6.0)

[0395] 5) Reaction solution Buffer B (0.05M / L MES pH6.5)

[0396] 6) Blocking solution Buffer C (0.05M / L TRIS-HCl + 1% W / V BSA pH 8.0)

[0397] 7) Storage solution Buffer D (0.05M / L TRIS-HCl + 1% W / V BSA + 10% W / V trehalose pH 8.0)

[0398] 8) 1.5mL centrifuge tube, 2mL centrifuge tube, 30mL centrifuge tube, 50mL centrifuge tube.

[0399] (2) Marking process

[0400] 1% microspheres were diluted 10 times or 5 times for labeling, preferably 10 times, and the microspheres were used at a concentration of 1 mg / mL.

[0401] 1) Cleaning microspheres

[0402] Take 50 μL of 1% microspheres and add them to a 1.5 mL centrifuge tube. Then add 450 μL of activation buffer A. Oscillate at 1000 rpm for 1 min. Then centrifuge at 14800 rpm for 30 min. Remove the supernatant. Add 400 μL of activation buffer A to reconstitute and wash once.

[0403] 2) Activated microspheres

[0404] Use activation buffer A to prepare 10 mg / mL EDC and Sulfo-NHS solutions. For example, weigh 1 mg EDC and dissolve it in 100 μL Buffer A. Add 50 μL Sulfo-NHS solution and 50 μL EDC solution to the washed microspheres, that is, the concentration of EDC and NHS is 1 mg / mL, and place them on a vortex oscillator at 1000 rpm for 30 minutes for activation.

[0405] 3) Cleaning after activation

[0406] After activation, wash and replace the solution with reaction solution Buffer B: After activation, centrifuge at 14800rpm for 20min, remove the supernatant, add 500μL reaction solution Buffer B, reconstitute, and wash once. After washing, centrifuge at 14800rpm for 20min, remove the supernatant, and add 500μL reaction solution Buffer B to reconstitute.

[0407] 4) Conjugated Antibodies

[0408] Add Galectin-3 protein detection antibody to the reconstituted microspheres and rotate to mix for 2 hours. The concentration range of different antibody labeling is 0.02-0.1 mg / mg.

[0409] Antibody volume = antibody labeling concentration x microsphere mass / antibody concentration

[0410] 5) Closure

[0411] After 2.0 h of coupling reaction, centrifuge at 14800 rpm for 20 min, remove the supernatant, add 500 μL of blocking solution Buffer C to reconstitute, place on a rotating incubator for rotation mixing and blocking for 60 min.

[0412] 6) Clean and store

[0413] After blocking, centrifuge at 14800rpm for 20min, remove the supernatant, add 250μL of Buffer D (microsphere final concentration 2mg / mL) to re-thaw. After re-suspending, store at 2-8℃ for later use. Dilute 10 times with the labeled diluent before spraying.

[0414] 2. Preparation of labeling pad:

[0415] The polyester film (30 cm*25 cm) was cut into 0.9 cm width and antibody-microsphere conjugates were sprayed with gold at a spray rate of 4 μL / cm. The label pad was then placed in a drying oven (37±1° C., humidity 10%-30%) for 23-24 hours.

[0416] 3. Preparation of coating antibody:

[0417] (1) Prepare the NC membrane and PVC base plate for later use.

[0418] (2) Detection line coating: Add 1 mg / mL Galectin-3 protein capture antibody to the coating diluent, mix thoroughly, and set aside.

[0419] (3) Quality control line: Measure the prepared coating diluent and add 0.5 mg / mL goat anti-mouse IgG, mix thoroughly and set aside.

[0420] (4) Set the film-scribing liquid volume to 1 μL / cm and perform the streaking operation. Place the NC film in a drying oven (temperature 50±1°C, humidity 10%-30%) and dry for 71-73 hours.

[0421] 4. Sample pad preparation:

[0422] The glass cellulose membrane (30cm*25cm) was cut into a width of 21mm, and the spray volume was set to 4μL / cm, the length was 300mm, and the interval was 6mm. This was repeated 3 times, and the gold spraying operation was performed using the sample pad treatment solution. Then, the marking pad was placed in a drying oven (37±1°C, humidity 10%-30%) and dried for 23-24 hours.

[0423] 5. Preparation of test strips:

[0424] Test strip preparation process (dry environment, temperature: 18-28°C, humidity 10%-30%)

[0425] (1) Place the dried marking pad, PVC base plate with NC film, absorbent paper, and sample pad on a Fig.10 Assemble as shown.

[0426] 1) Pasting of absorbent paper: Peel off the protective film of the absorbent paper area of ​​the PVC base plate, align one end of the cut absorbent paper with the B section of the PVC base plate and paste it, and place the other end on the NC film.

[0427] 2) Pasting of the marking pad: peel off the protective film of the marking pad area of ​​the PVC base plate, align the prepared marking pad with one end of the marking pad area (close to the sample pad), and place the other end on the NC film.

[0428] 3) Attachment of sample pad: Peel off the protective film on the sample pad or filter membrane area of ​​the PVC base plate, align one end of the cut sample pad with end A of the PVC base plate, and place the other end on the marking pad.

[0429] (2) Set the cutting width to 3.3 mm, and place the assembled gold label large board on the cutting machine for cutting. After the cutting is completed, collect the cut test strips into a test strip sealing box (humidity <30%) for storage.

[0430] (3) The test strips are packaged in a shell, with one test card and one bag of desiccant in each bag to seal the test cards.

[0431] 6. Test samples:

[0432] The method for measuring the content of Galectin-3 full-length protein or Galectin-3 total protein in biological samples using the above-mentioned fluorescence chromatography kit and the supporting instrument comprises the following specific steps:

[0433] (1) After pre-equilibration of the serum sample, standard sample, and positive control sample at room temperature, dilute the serum sample by half with biological sample diluent (if a sample with very high concentration is encountered, a quarter and an eighth dilution can be performed); dilute the standard sample to eight gradients of 100 ng / mL, 50 ng / mL, 25 ng / mL, 10 ng / mL, 5 ng / mL, 2.5 ng / mL, 1 ng / mL, and 0.5 ng / mL; directly use the standard sample diluent as the negative control;

[0434] (2) Take out the reagent card that has been dried and sealed and place it on a horizontal table. Use a pipette to add 70 μL of the calibrator and sample to the sample well. After reacting for 15 minutes, insert it into the immunoassay analyzer for testing to obtain the corresponding T / C value.

[0435] (3) The T / C value is positively correlated with the Galectin-3 protein content in the sample. A standard curve is created with the standard concentration as the X-axis and the T / C value as the Y-axis. Fig.11 or Fig.12 or Fig.13 (Galectin-3 protein cleaved by MMP2 was added as a control).

[0436] (4) Calculation of Galectin-3 protein concentration in the sample: If the coefficient of variation between the measured value of the positive control sample and the labeled value is less than 10%, it means that the measurement process is reliable. The concentration of human Galectin-3 protein in the measured sample can be calculated based on the standard curve obtained in the previous step.

[0437] Example 5 Application of Antibodies in Galectin-3 Protein Chemiluminescence Detection Kit

[0438] The present invention provides a chemiluminescent detection kit for detecting the full-length Galectin-3 protein in human body fluid samples, and the kit adopts a double antibody sandwich detection method. The present invention provides a chemiluminescent detection kit for detecting the full-length Galectin-3 protein in human body fluid samples. The Galectin-3 monoclonal antibodies, one of which is an epitope antibody within the amino acid range of positions 1-62 of the N-terminal protein of Galectin-3, and the other antibody is an epitope antibody within the amino acid range of positions 63-250 of the Galectin-3 protein as a detection antibody, and the best combination is selected after pairing, such as the capture antibody is UV4E4, and the detection antibody is E15F10.

[0439] The present invention also provides a chemiluminescent detection kit for detecting Galectin-3 total protein in human fluid samples, and the kit adopts a double antibody sandwich detection method. The present invention provides a chemiluminescent detection kit for detecting Galectin-3 total protein in human fluid samples. The Galectin-3 protein capture antibody and the Galectin-3 protein detection antibody are respectively antibodies with different epitopes within the range of amino acids 1-62 at the N-terminus of the Galectin-3 protein, and the best combination is selected after pairing, such as the capture antibody is Q1E2 and the detection antibody is E15F10. Or the Galectin-3 monoclonal antibodies are respectively antibodies with different epitopes within the range of amino acids 63-250 of the Galectin-3 protein, and the best combination is selected after pairing, such as the capture antibody is UV4E4 and the detection antibody is Y7E12.

[0440] The chemiluminescent detection kit for the full-length Galectin-3 protein in this embodiment and the chemiluminescent detection kit for the total Galectin-3 protein are basically the same except for the different antibody combinations. The specific implementation steps are as follows:

[0441] The kit of this embodiment includes a magnetic separation reagent, a first reagent, a second reagent, and a Galecin-3 protein series calibrator.

[0442] 1. The preparation method of magnetic separation reagent is:

[0443] The magnetic particles were resuspended with 0.05 mol / L, pH 8.0 boric acid buffer, and the concentration of the magnetic particles after resuspension was 6 mg / mL; Galecin-3 monoclonal antibody was added, the mass ratio of magnetic particles to Galecin-3 monoclonal antibody was 80:1, mixed, 1 mol / L ammonium sulfate solution was added, the volume of ammonium sulfate solution added was 1 / 2 of the sum of the volumes of magnetic particles and Galecin-3 monoclonal antibody, and suspended at 25°C for reaction for 8 hours; after the reaction, magnetic separation was performed, the supernatant was removed, and the precipitate was added with blocking solution, 250 μL of blocking solution was added for every 10 mg of magnetic beads, and suspended at 25°C for reaction for 1 hour; then washed three times with Tris buffer (pH 7.4) containing 1% Tween-20, and finally 0.007 mol / L pH 7.4 TRIS buffer containing 0.06% BSA was added, so that the concentration of magnetic particles coated with Galecin-3 monoclonal antibody was 0.1 mg / mL.

[0444] 2. The preparation method of the first reagent is:

[0445] The coupling agent N-hydroxysuccinimide biotin ester (BNHS) was dissolved in DMSO to prepare a BNHS solution, wherein the concentration of BNHS was 12 mmol / L; the BNHS solution was added to the Galecin-3 monoclonal antibody solution at a molar ratio of BNHS to Galecin-3 monoclonal antibody of 15:1, mixed, and placed at 25°C for 50 minutes, and then 1.5 mol / L, pH 7.4 TRIS buffer was added to terminate the reaction; then 0.03 mol / L, pH 7.4 TRIS buffer containing 2% BSA was added to dilute the above solution, so that the concentration of the BNHS-labeled Galecin-3 monoclonal antibody was 2 μg / mL.

[0446] 3. The preparation method of the second reagent is:

[0447] 0.3 mg / mL alkaline phosphatase was added to 10 mg / mL EDC coupling agent, and the mixture was allowed to stand at 20°C for 30 minutes. The mixture was passed through a G-25 gel column for desalting, and the activated alkaline phosphatase was collected. 0.6 mg / mL streptavidin was added to the activated alkaline phosphatase solution, and the molar ratio of streptavidin to alkaline phosphatase was 1:1. The mixture was stirred and mixed at 20°C for 5 hours. 1.0 mol / L glycine solution was added, and the mixture was stirred and mixed for 1 hour. Then, 0.06 mol / L pH 6.8 HEPES buffer containing 0.3% BSA was added to dilute the concentration of the streptavidin-labeled alkaline phosphatase solution to 1.5 μg / mL.

[0448] 4. Preparation of Galecin-3 protein series calibrators:

[0449] The Galecin-3 protein was diluted with a protective agent to seven calibration concentrations: 60 ng / mL, 40 ng / mL, 20 ng / mL, 10 ng / mL, 5 ng / mL, 1 ng / mL and 0.1 ng / mL. The protective agent was directly selected as a negative control; the protective agent buffer was 0.08 mol / L pH 7.4 TRIS buffer containing 1% BSA.

[0450] 5. How to use this kit:

[0451] (1) Add 50 μL of the sample to be tested and the calibrator to the test tube, then add 50 μL of the magnetic separation reagent and 50 μL of the first reagent, mix well, and incubate at 37°C for 10 min;

[0452] (2) Add 50 μL of the second reagent, mix well, and incubate at 37°C for 3 min;

[0453] (3) Place the test tube in a magnetic separator, add a magnetic field, let it settle in the magnetic field for 1 min, remove the supernatant, and then wash it repeatedly with a cleaning solution for 3 times;

[0454] (4) Add 100 μL of alkaline phosphatase-catalyzed luminescent substrate, suspend for 3 seconds, and then detect using a luminescence detector.

[0455] (5) According to the relative luminescence intensity (RLU) of the sample to be tested, the concentration of GALECIN-3 in the sample is calculated from the standard curve.

[0456] Example 6 Application of Antibodies in Single Molecule Immunoassay Array Detection Kits

[0457] The present invention provides a single molecule immune array detection kit for detecting the full-length Galectin-3 protein in human body fluid samples, and the kit adopts a double antibody sandwich detection method. The present invention provides a single molecule immune array detection kit for detecting the full-length Galectin-3 protein in human body fluid samples. The Galectin-3 monoclonal antibodies, one of which is an epitope antibody within the amino acid range of positions 1-62 of the N-terminal protein of Galectin-3, and the other antibody is an epitope antibody within the amino acid range of positions 63-250 of the Galectin-3 protein as a detection antibody, and the best combination is selected after pairing, such as the capture antibody is UV4E4 and the detection antibody is E15F10.

[0458] The present invention also provides a single molecule immune array detection kit for detecting Galectin-3 total protein in human fluid samples, and the kit adopts a double antibody sandwich detection method. The present invention provides a single molecule immune array detection kit for detecting Galectin-3 total protein in human fluid samples. The Galectin-3 protein capture antibody and the Galectin-3 protein detection antibody are respectively antibodies with different epitopes within the range of amino acids 1-62 at the N-terminus of the Galectin-3 protein, and the best combination is selected after pairing, such as the capture antibody is Q1E2 and the detection antibody is E15F10. Or the Galectin-3 monoclonal antibodies are respectively antibodies with different epitopes within the range of amino acids 63-250 of the Galectin-3 protein, and the best combination is selected after pairing, such as the capture antibody is UV4E4 and the detection antibody is Y7E12.

[0459] The single molecule immunoarray detection kit for the Galectin-3 full-length protein and the single molecule immunoarray detection kit for the Galectin-3 total protein in this embodiment are basically the same except for the different antibody combinations. The single molecule immunoarray detection kit for the Galectin-3 full-length protein or the single molecule immunoarray detection kit for the Galectin-3 total protein provided in this embodiment includes magnetic beads coated with capture antibodies, biotinylated detection antibodies, Galectin-3 standards of known concentrations, streptavidin-β-galactosidase solution, fluorescent substrate solution, sample diluent, magnetic bead diluent, and SBG diluent. The specific implementation steps are as follows:

[0460] The capture antibody-coated magnetic beads were prepared as follows:

[0461] The capture antibody was treated with magnetic bead coupling buffer (BCB) through an ultrafiltration tube for liquid replacement to collect Galectin-3 capture antibody; the magnetic beads were repeatedly washed with BCB for 3 times, and then activated with EDC (0.3 mg / mL) at 4°C for 30 min; the activated magnetic beads were washed with BCB for 2 times, and then activated with 1.4×10 9 / mL) and the replaced capture antibody (0.2mg / mL) were coupled at 4°C for 2h; after repeated washing with magnetic bead cleaning solution for 3 times, the uncoupled sites were blocked with magnetic bead blocking buffer; finally, the magnetic bead cleaning solution was washed and stored with magnetic bead diluent to obtain Galectin-3 capture antibody-coated magnetic beads.

[0462] Preparation of biotinylated Galectin-3 detection antibody:

[0463] The detection antibody is replaced with a biotinylation reaction buffer through an ultrafiltration tube; the detection antibody is mixed with NHS-PEG4-Biotin at room temperature for 30 minutes; after the reaction, the biotinylation reaction buffer is used for purification through an ultrafiltration tube to obtain a biotinylated Galectin-3 detection antibody stored in the biotinylation reaction buffer. The molar ratio of the detection antibody to NHS-PEG4-Biotin is 1:40.

[0464] Dilution method of standard solution and SBG solution:

[0465] The Galectin-3 standard with known concentration was diluted with sample diluent to 7 concentration points of 60 ng / mL, 40 ng / mL, 20 ng / mL, 10 ng / mL, 5 ng / mL, 1 ng / mL and 0.1 ng / mL as the Galectin-3 standard for the fitting curve;

[0466] The SBG solution was diluted to 150 pM using SBG diluent as the working solution.

[0467] Magnetic bead coupling buffer, magnetic bead washing solution, magnetic bead diluent, biotinylation reaction buffer, blocking buffer, fluorescent substrate, sample diluent, SBG and SBG diluent were all purchased from Quanterix.

[0468] The specific detection steps of the kit of this embodiment are as follows:

[0469] (1) Import the HD-X Homebrew Assay Definition 1 file on the Quanterix HD-X instrument and set the experimental conditions: two-step method, i.e., the reaction time of capture antibody-coated magnetic beads, sample, and biotinylated detection antibody is 35 min, the SBG reaction time is 5 min, and the standard curve concentration points are set (60 ng / mL, 40 ng / mL, 20 ng / mL, 10 ng / mL, 5 ng / mL, 1 ng / mL and 0.1 ng / mL, 0 ng / mL). Dilute the sample to be tested with sample diluent to 1-10 times (depending on the sample measurement volume).

[0470] (2) Load the Galectin-3 capture antibody-coated magnetic bead solution (25 μL), biotinylated Galectin-3 detection antibody solution (20 μL), SBG working solution (100 μL), RGP solution (50 μL), and a 96-well plate with standards (100 μL) and samples (100 μL) into the instrument.

[0471] Informal Sequence Listing

[0472] SEQ ID NO:1

[0473] Met Ala Asp Asn Phe Ser Leu His Asp Ala Leu Ser Gly Ser Gly Asn ProAsn Pro Gln Gly Trp Pro Gly Ala Trp Gly Asn Gln Pro Ala Gly Ala Gly Gly TyrPro Gly Ala Ser Tyr Pro Gly Ala Tyr Pro Gly Gln Ala Pro Pro Gly Ala Tyr ProGly Gln Ala Pro Pro Gly Ala

[0474] SEQ ID NO:2

[0475] Tyr Pro Gly Ala Pro Gly Ala Tyr Pro Gly Ala Pro Ala Pro Gly Val TyrPro Gly Pro Pro Ser Gly Pro Gly Ala Tyr Pro Ser Ser Gly Gln Pro Ser Ala ThrGly Ala Tyr Pro Ala Thr Gly Pro Tyr Gly Ala Pro Ala Gly Pro Leu Ile Val ProTyr Asn Leu Pro Leu Pro Gly Gly Val Val Pro Arg Met Leu Ile Thr Ile Leu GlyThr Val Lys Pro Asn Ala Asn Arg Ile Ala Leu Asp Phe Gln Arg Gly Asn Asp ValAla Phe His Phe Asn Pro Arg Phe Asn Glu Asn Asn Arg Arg Val Ile Val Cys AsnThr Lys Leu Asp Asn Asn Trp Gly Arg Glu Glu Arg Gln Ser Val Phe Pro Phe GluSer Gly Lys Pro Phe Lys Ile Gln Val Leu Val Glu Pro Asp His Phe Lys Val AlaVal Asn Asp Ala His Leu Leu Gln Tyr Asn His Arg Val Lys Lys Leu Asn Glu IleSer Lys Leu Gly Ile Ser Gly Asp Ile Asp Leu Thr Ser Ala Ser Tyr Thr Met Ile

[0476] SEQ ID NO:3

[0477] Thr Tyr Val Asp Tyr

[0478] SEQ ID NO:4

[0479] Gln Met Ala Val His Asn Ser Thr Lys Asp Gly Asn Pro Thr Leu Arg

[0480] SEQ ID NO:5

[0481] Gly Asp Leu Ile

[0482] SEQ ID NO:6

[0483] Ser Gly Ser Gly Phe Gly Asp Tyr Val Asn Ser Asp Asn Val

[0484] SEQ ID NO:7

[0485] Gly Ala Thr Ser Arg Arg Val

[0486] SEQ ID NO:8

[0487] Gly Ser Gly Gly Gly Tyr Val Asn Ser Arg

[0488] SEQ ID NO:9

[0489] Ala Ile His Asp Phe

[0490] SEQ ID NO:10

[0491] Thr Arg Asn Ala Asp Asp Phe Lys Gly Trp Ile Asn Lys Ser Thr Tyr

[0492] SEQ ID NO:11

[0493] Ser Arg His Phe Ala Asp Trp Tyr

[0494] SEQ ID NO:12

[0495] Leu Thr Ser Ser Gln His Ser Thr Ile Glu Thr Tyr

[0496] SEQ ID NO:13

[0497] Val Ser Leu Ser Thr Gly Asp Glu Lys Asp Gly

[0498] SEQ ID NO:14

[0499] Gly Val Glu Gln Phe Val Tyr Val Gly Asp Thr Ile Glu

[0500] SEQ ID NO:15

[0501] Asp Leu Asn Ser Tyr

[0502] SEQ ID NO:16

[0503] Glu Thr Asn Tyr Asn Glu Lys Phe Lys Gly Ile Tyr Pro Gly Glu TrpAspSEQ ID NO:17

[0504] Gly Ser Gly Arg Gly Leu Ala Tyr Ala Trp

[0505] SEQ ID NO:18

[0506] Arg Ser Arg Gln Ser Ile Gly Asn Thr Tyr Leu Glu Val Tyr Ser Asn

[0507] SEQ ID NO:19

[0508] Asn Arg Phe Ser Lys Val Ser

[0509] SEQ ID NO:20

[0510] Gly Ser His Tyr Thr Phe Gln Val Pro

[0511] SEQ ID NO:21

[0512] Asp Met Ser Asn Tyr

[0513] SEQ ID NO:22

[0514] Ala Asp Gly Tyr Thr Tyr Val Lys Gly Thr Ile Ser Gly Tyr Pro Asp Ser

[0515] SEQ ID NO:23

[0516] Gly Asp Trp Tyr Pro Ser Thr Phe Ala

[0517] SEQ ID NO:24

[0518] Ile Val Phe Ser Asn Glu Lys Ser Ser Gln Ser Gly Ile Thr Tyr Leu

[0519] SEQ ID NO:25

[0520] Asn Arg Ser Lys Val Ser Phe

[0521] SEQ ID NO:26

[0522] Gly Ser His Trp Thr Phe Gln Leu Pro

[0523] SEQ ID NO:27

[0524] Glu Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Lys Gln SerLeu Ser Leu Thr Cys Thr Val Ser Val Gly Thr Val Gly Met Pro Pro Gly Leu ThrTyr Val Asp Tyr Thr Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp IleGly Gln Met Ala Val His Asn Ser Thr Lys Asp Gly Asn Pro Thr Leu Arg Arg ValThr Ile Ser Glu Asp Thr Ser Lys Asn Gln Phe Pro Leu Gln Leu Ser Ser Val ThrGlu Ala Asp Thr Ala Leu Tyr Phe Cys Thr Arg Gly Asp Leu Ile Ala Cys His TyrTrp Gly Gln Gly Thr Ser Val Thr Val Ser Ser

[0525] SEQ ID NO:28

[0526] Gln Ile Gln Leu Thr Gln Ser Pro Ala Thr His Leu Val Ser Pro Gly GlySer Ile Thr Ile Ser Cys Ser Gly Ser Gly Phe Gly Asp Tyr Val Asn Ser Asp AsnVal Trp Phe Leu Gln Arg Pro Gly Gln Ala Pro Glu Leu Leu Ile Tyr Gly Ala ThrSer Arg Arg Val Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp PheThr Leu Gly Ile Ser Asn Val Gln Ala Glu Asp Leu Gly Ile Tyr Tyr Cys Gly SerGly Gly Gly Tyr Val Asn Ser Arg Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys

[0527] SEQ ID NO:29

[0528] Glu Val Gln Leu Val Gly Ser Gly Gly Gly Leu Val Gln Pro Lys Gly SerLeu Ser Leu Ser Cys Lys Ala Ser Val Gly Thr Val Gly Met Ala Ile His Asp PheIle Asn Trp Ile Arg Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Arg Thr ArgAsn Ala Asp Asp Phe Lys Gly Trp Ile Asn Lys Ser Thr Tyr Arg Val Thr Ile SerVal Asp Thr Ser Lys Asn Gln Phe Pro Leu Gln Leu Asn Ser Val Thr Glu Ala AspThr Ala Leu Tyr Phe Cys Val Arg Ser Arg His Phe Ala Asp Trp Tyr Tyr Trp GlyGln Gly Thr Ser Val Thr Val Ser Ser

[0529] SEQ ID NO:30

[0530] Asp Ile Glu Leu Thr Gln Ser Pro Ala Tyr Val Ala Ala Ser Leu Gly GlnArg Ile Ser Ile Ser Cys Leu Thr Ser Ser Gln His Ser Thr Ile Glu Thr Tyr TrpPhe Leu Gln Arg Pro Gly Gln Ser Pro Glu Leu Leu Ile Tyr Val Ser Leu Ser ThrGly Asp Glu Lys Asp Gly Gly Val Pro Ala Phe Ser Gly Ser Gly Ser Gly ThrAsp Phe Thr Leu Gly Ile Ser Asn Val Gln Ala Glu Asp Leu Gly Ile Tyr Tyr CysGly Val Glu Gln Phe Val Tyr Val Gly Asp Thr Ile Glu Phe Gly Gly Gly Thr LysLeu Glu Ile Lys

[0531] SEQ ID NO:31

[0532] Glu Val Gln Leu Gln Glu Ser Gly Ala Gly Leu Val Lys Pro Ser Gly SerLeu Ser Leu Thr Cys Thr Val Ser Asp Leu Asn Ser Tyr Met Asn Trp Val Arg GlnAla Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Glu Thr Asn Tyr Asn Glu Lys PheLys Gly Ile Tyr Pro Gly Glu Trp Asp Arg Ile Thr Ile Ser Arg Asp Thr Ser LysAsn Gln Phe Ser Leu Arg Leu Ser Ser Leu Thr Ser Ala Asp Thr Ala Val Tyr TyrCys Ala Arg Gly Ser Gly Arg Gly Leu Ala Tyr Ala Trp Thr Trp Gly Gln Gly ThrSer Val Thr Val Ser Ala

[0533] SEQ ID NO:32

[0534] Asp Ile Gln Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly GluThr Val Thr Ile Ser Cys Arg Ser Arg Gln Ser Ile Gly Asn Thr Tyr Tyr Leu Glu ValTyr Ser Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr AsnArg Phe Ser Lys Val Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly ThrAsp Phe Thr Leu Thr Ile Ser Arg Val Glu Glu Asp Phe Ala Ile Tyr Tyr CysGly Ser His Tyr Thr Phe Gln Val Pro Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys

[0535] SEQ ID NO:33

[0536] Glu Val Gln Leu Lys Glu Ser Gly Gly Gly Leu Val Gln Pro Lys Gln SerLeu Lys Leu Ser Cys Thr Val Ser Asp Met Ser Asn Tyr Met Ser Trp Val Arg GlnThr Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ala Asp Gly Tyr Thr Tyr Val LysGly Thr Ile Ser Gly Tyr Pro Asp Ser Arg Ile Thr Ile Ser Arg Asp Thr Ser LysAsn Gln Phe Ser Leu Lys Leu Asn Ser Leu Thr Ser Ala Asp Thr Ala Val Tyr TyrCys Ala Arg Gly Asp Trp Tyr Pro Ser Thr Phe Ala Thr Trp Gly Gln Gly Thr SerVal Thr Val Ser Ala

[0537] SEQ ID NO:34

[0538] Gly Ile Leu Leu Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Pro Gly GluLeu Val Thr Ile Thr Cys Ile Val Phe Ser Asn Glu Lys Ser Ser Gln Ser Gly IleThr Tyr Leu Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Ser Glyn Ser Pro Gly Ser Val Arsp Ar Phe Ser Gly Ser Gly Ser Gly ThrAsp Phe Thr Leu Thr Ile Ser Arg Val Glu Ala Glu Asp Phe Ala Ile Tyr Tyr CysGly Ser His Trp Thr Phe Gln Leu Pro Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys

[0539] SEQ ID NO:35

[0540] ATGGGTGCCAGTGTCTCTTAGGA

[0541] SEQ ID NO:36

[0542] GAAGCCTCCAAGACCTTAGAAGGGAA

[0543] SEQ ID NO:37

[0544] AAGCAGTGGTATCAACGCAGA

[0545] SEQ ID NO:38

[0546] AACATTGATGTCTTTGGGGTAGAA

[0547] SEQ ID NO:39

[0548] AATCGTACACACCAGTGTGTGGG

[0549] SEQ ID NO:40

[0550] AGGGATCCAGAGTTCCAGGT。

Claims

1. An antibody or an antigen-binding portion thereof, wherein the antibody is capable of binding to human galectin-3, and the binding epitope is located in the N-terminal 1-62 amino acid sequence region of human galectin-3 as shown in SEQ ID NO:

1.

2. The antibody or antigen-binding portion thereof of claim 1, wherein the antibody comprises HCDR1 shown in SEQ ID NO:3, HCDR2 shown in SEQ ID NO:4, HCDR3 shown in SEQ ID NO:5, LCDR1 shown in SEQ ID NO:6, LCDR2 shown in SEQ ID NO:7, and LCDR3 shown in SEQ ID NO:8; or The antibody comprises HCDR1 shown in SEQ ID NO:9, HCDR2 shown in SEQ ID NO:10, HCDR3 shown in SEQ ID NO:11, LCDR1 shown in SEQ ID NO:12, LCDR2 shown in SEQ ID NO:13 and LCDR3 shown in SEQ ID NO:

14.

3. An antibody or an antigen-binding portion thereof, wherein the antibody is capable of binding to human galectin-3, and the binding epitope is located in the N-terminal 63-250 amino acid sequence region of human galectin-3 as shown in SEQ ID NO:

2.

4. The antibody or antigen-binding portion thereof of claim 3, wherein the antibody comprises HCDR1 shown in SEQ ID NO: 15, HCDR2 shown in SEQ ID NO: 16, HCDR3 shown in SEQ ID NO: 17, LCDR1 shown in SEQ ID NO: 18, LCDR2 shown in SEQ ID NO: 19, and LCDR3 shown in SEQ ID NO: 20; or The antibody comprises HCDR1 shown in SEQ ID NO:21, HCDR2 shown in SEQ ID NO:22, HCDR3 shown in SEQ ID NO:23, LCDR1 shown in SEQ ID NO:24, LCDR2 shown in SEQ ID NO:25 and LCDR3 shown in SEQ ID NO:

26.

5. An antibody combination product comprising a first antibody and a second antibody, wherein the first antibody and the second antibody are selected from the antibody or antigen-binding portion thereof according to any one of claims 1 to 4.

6. The antibody combination product according to claim 5, in, The first antibody is selected from the antibody or antigen binding portion thereof of any one of claims 1 to 2 and the second antibody is selected from the antibody or antigen binding portion thereof of any one of claims 3 to 4; or The first antibody and the second antibody are both selected from the antibody or antigen-binding portion thereof according to any one of claims 1 to 2; or The first antibody and the second antibody are both selected from the antibody or antigen-binding portion thereof according to any one of claims 3 to 4.

7. The antibody combination product of claim 5, wherein the first antibody is labeled with a detectable marker or the second antibody is labeled with a detectable marker.

8. The antibody combination product of claim 7, wherein the detectable label is selected from the group consisting of an enzyme, a prosthetic group, a fluorescent substance, a luminescent substance, a latex particle, a gold particle, a bioluminescent substance, and a radioactive substance.

9. A kit for detecting the level of Galectin-3 in a sample from a human subject, comprising the antibody combination product of any one of claims 5 to 8. 10 . The kit according to claim 9 , wherein the level of Galectin-3 is the level of human Galectin-3 full-length protein or the level of human Galectin-3 total protein.

11. The kit according to claim 9, wherein the kit detects the level of galectin-3 using a double antibody sandwich method; The double antibody sandwich method is selected from ELISA, colloidal gold, immunochromatography, surface enhanced Raman scattering immunochromatography, chemiluminescence, microfluidics and single molecule immunoarray.

12. The kit of claim 11, wherein the kit is an ELISA detection kit, a colloidal gold detection kit, an immunochromatography detection kit, a surface enhanced Raman scattering immunochromatography detection kit, a chemiluminescence detection kit, a microfluidics detection kit or a single molecule immunoarray detection kit.

13. A kit for detecting the level of total Galectin-3 protein in a sample from a human subject, comprising the antibody or antigen-binding portion thereof according to any one of claims 1 to 4.

14. Use of the antibody or antigen binding portion thereof according to any one of claims 1 to 4 or the antibody combination product according to any one of claims 5 to 8 in the preparation of a kit for detecting the level of Galectin-3 in a biological sample.

15. Use of the antibody or antigen-binding portion thereof according to any one of claims 1 to 4 or the antibody combination product according to any one of claims 5 to 8 in the preparation of a kit for diagnosing or assisting in the diagnosis of a disease, wherein the disease is selected from cardiovascular disease, tumor, rheumatic immune disease, kidney disease, respiratory system disease, digestive system disease or infectious disease.

16. The use according to claim 15, in, The cardiovascular disease is heart failure, coronary heart disease or atrial fibrillation; The tumor is thyroid cancer, breast cancer, ovarian cancer, gastric cancer, esophageal cancer, non-small cell lung cancer, colon adenocarcinoma or endometrial cancer; The rheumatic immune disease is rheumatoid arthritis; The kidney disease is chronic kidney disease; The respiratory disease is bronchial asthma, chronic obstructive pulmonary disease or primary Sjögren's syndrome; The digestive system disease is ulcerative colitis or liver cirrhosis; or The infectious disease is sepsis.

17. A method for diagnosing or assisting in the diagnosis of a disease, the method comprising: Labeling the first antibody or the second antibody in the antibody combination product of claim 5 with a detectable marker; The level of human galectin-3 is detected by using a double antibody sandwich method, wherein the level of human galectin-3 is the level of human galectin-3 full-length protein or the level of human galectin-3 total protein; wherein the double antibody sandwich method is selected from ELISA, colloidal gold, immunochromatography, surface enhanced Raman scattering immunochromatography, chemiluminescence, microfluidics and single molecule immunoarray; The disease is selected from cardiovascular disease, tumor, rheumatic immune disease, kidney disease, respiratory system disease, digestive system disease and infectious disease.

18. The method of claim 17, in, The cardiovascular disease is heart failure, coronary heart disease or atrial fibrillation; The tumor is thyroid cancer, breast cancer, ovarian cancer, gastric cancer, esophageal cancer, non-small cell lung cancer, colon adenocarcinoma or endometrial cancer; The rheumatic immune disease is rheumatoid arthritis; The kidney disease is chronic kidney disease; The respiratory disease is bronchial asthma, chronic obstructive pulmonary disease or primary Sjögren's syndrome; The digestive system disease is ulcerative colitis or liver cirrhosis; or The infectious disease is sepsis.

19. The method of claim 17, wherein the level of human Galectin-3 is the level of human Galectin-3 full-length protein or the level of human Galectin-3 total protein.

Citation Information

Patent Citations

  • Galectin-3 immunoassay

    CN102257390A

  • Galectin-3 test kit

    CN107383192A

  • Galectin-3 mouse hybridoma cell, monoclonal antibody, detection kit and detection method

    CN113999817A

  • Immunoassay of galectin-3

    CN115746134A

  • Antibodies to galectin-3 and methods of use thereof

    WO2022125482A1